Thursday, February 28, 2019

Dynavax Technologies Corporation (DVAX) Q4 2018 Earnings Conference Call Transcript

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it

Image source: The Motley Fool.

Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2018 Earnings Conference Call February 26, 2019, 4:30 p.m. ET

Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

Operator

Good day, ladies and gentlemen and welcome to Dynavax Technologies fourth quarter and full year 2018 conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press *0 on your telephone keypad. As a reminder, this conference is being recorded.

I would now like to introduce your host for today's conference, Miss Heather Rowe, Vice President of Investor Relations and Corporate Communication. You may begin.

Heather Rowe -- Vice President of Investor Relations and Corporate Communications

Thank you, Operator. Good afternoon. Welcome to the Dynavax fourth quarter and full year 2018 financial results conference call. With me today are Eddie Gray, Chief Executive Officer, Rob Janssen, Chief Medical Officer, Michael Ostrach, Chief Financial Officer, and Ryan Spencer, Vice President, Commercial Operations. We issued a press release this afternoon and also posted slides to accompany this presentation. The slides can be found under the investor relations section of our website under events and presentations.

Before we begin, I advise that we will be making forward-looking statements, including statements regarding clinical and financial information, expectations, and anticipated key events. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially. These risks are summarized in today's press release and are detailed in the risk factors section of our current 10-Q and 10-K periodic report filed with the SEC, which we encourage you to review.

With that, I'll now turn the call over to Eddie.

Eddie Gray -- Chief Executive Officer and Director

Thank you, Heather and thank you, everyone for joining us today to review our fourth quarter and full year 2018 results. 2018 was an important year of execution for Dynavax, both for the Hepislav-B commercial program and our SD-101 immuno-oncology clinical program.

Our pipeline can be seen on slide three. The backbone of this pipeline is built on an expertise in discovering and developing TLR agonists that stimulate the immune system to prevent infectious disease and treat cancer. Against that backdrop, I'll now highlight key accomplishments from the past year.

First, as you can see on slide four, Hepislav-B is poised to become the standard of care hepatitis B adult vaccine and for good reason. It offers clinical advantage over the competition. Namely, it is the only two-dose hepatitis vaccine and it has consistently protected more than 90% of adult patients, demonstrating significantly higher sero-protection rates than the market leader in head-to-head studies.

We launched Hepislav-B in 2018 with a 60-person field sales team, covering over 75% of the target market. Our efforts to shift market share from our competitors are beginning to pay off and we are establishing a solid base within institutional accounts, ensuring a future of long-term stable revenue generation.

Let me highlight some recent wins as shown on slide five. Today, we've reported Hepislav-B net sales of $3.9 million for the fourth quarter, a little more than the estimate we provided in January. This compares to $1.5 million for the third quarter. We reiterate our expectation, but Hepislav operations will be profitable by the end of the year and we believe that over time, Hepislav can reach peak gross US sales of around $500 million.

While we are confident with our year-end goal, we know we should still expect monthly and quarterly fluctuations and that the rate of growth each quarter will also fluctuate. Each large institutional customer follows a unique decision and purchase process and their associated timelines vary.

In 2019, the timing of purchases by new customer entrants are very influential. Over time, though, they make repeat orders, which settle into a more predictable pattern, thus becoming something like an annuity. Whilst this trend is beginning in 2019, obviously, the genuine power of the annuity continues to grow over time.

Let me discuss some of the recent progresses that we've made. In 2018, more than 1,200 individual customers purchased Hepislav-B. More than 80% of the doses sold to date were purchased by repeat customer purchase. As previously announced in January, Hepislav-B became available in all of the Sam's Club pharmacy locations.

In addition, we have begun sales into two of the four top national retail pharmacy chains and contracting efforts are under way to secure additional pharmacy partners. These wins represent an important step toward building our pharmacy presence to ensure and support future growth in the diabetes market.

Beyond our retail pharmacy progress, we have other recent wins, including large State Departments of Corrections, multiple Department of Defense customers, as well as State and County Health Departments through the CDC for Adult program, which became operational in January.

In addition, since our November call, we've had 17 new PNT approvals within the top 100 accounts, which means we've now passed 53 of our top 100 accounts through this important point in the process. As of last week, we've moved over 590 customers in total through PNT approval and they represent in excess of 36% of the target market potential.

In the United States, the market appears to be fairly stable around 2 million to 2.5 million adults, who are vaccinated annually against hepatitis B. Within this market are areas for growth, including increasing second-dose compliance and once we've gained market share in retail pharmacies, focus on diabetic patients.

In summary, as you can see on slide six, we believe that we're well-positioned to drive sustained revenue growth. We have a compelling commercial profile and an established concentrated market that we can convert into an annuity.

I'll now turn the call over to our Chief Medical Officer, Rob Janssen, to discuss the immuno-oncology clinical program.

Robert Janssen -- Chief Medical Officer

Thanks, Eddie. Our lead candidate is SD-101, our optimized TLR9 agonist, as shown on slide eight. We're evaluating this intertumoral TLR9 agonist in several clinical studies to assess its safety and activity. This includes a phase II study in combination with the anti-PD-1 therapy Pembrolizumab in patients within advanced melanoma and in patients with head and neck squamous cell carcinoma.

While the current trials are in combination with Pembrolizumab, intertumoral SD-101 has systemic single-agent activity as we demonstrated in the study of lymphoma patients. In this study, intertumoral SD-101-induced abscopal responses in the absence of any other systemic therapy by producing regression in non-injected tumors.

We've consistently demonstrated that SD-101 adds meaningful clinical benefit to Pembrolizumab therapy. As shown on slide nine and presented at ESMO last year, tumors [inaudible] with SD-101 in patients with advanced melanoma naïve to anti-PD-1 therapy led to a 70% overall response rate or ORR. There was a 68% ORR in non-injected lesions, including visceral metastases in the lung and liver.

In addition, responses appear to be independent of PDL-1 expression in unselected samples. We also announced the encouraging early data from additional trials, including patients with melanoma refractory or resistant to anti-PD-1 therapy and patients with head and neck squamous cell carcinoma who are naïve to anti-PD-1 therapy. You can see these data on slides 10 and 11.

The response rates were better than what we're seeing with Pembrolizumab alone. In both trials, reported data were from 8-milligram cohorts. We've recently completed enrollment in 2-milligram cohorts and plan to report on these data later this year.

Now, importantly, the combination of SD-101 and Pembrolizumab remains well-tolerated with adverse events related to SD-101 being transient, mild to moderate, flu-like symptoms. SD-101 and Pembrolizumab are also being evaluated in a randomized investigational treatment arm for the ongoing I-SPY2 trial for neoadjuvant treatment of locally advanced breast cancer. The combination is being added to standard of care in the new treatment arm.

This trial is important for several reasons. Notably, it's a controlled study. Recall the I-SPY2 trial is a standing phase II randomized controlled multi-center study with an innovative adaptive design intended to rapidly screen and identify promising new treatments in specific subgroups of women with newly diagnosed high-risk, locally advanced breast cancer.

The primary outcome measure of this study is the pathologic complete response rate, which was proposed by FDA in 2012 as a regulatory endpoint to expedite development of drugs for these types of patients. SD-101, which can be administered directly into these lesions is well-suited for this indication from which there's a high unmet net. We look forward to seeing how SD-101 might help make available new more effective treatments for women with advanced breast cancer.

We're also developing a TLR9 agonist, DV281, that's designed for delivery to the lung as an inhaled treatment for lung cancer or other cancers metastasizing to the lung. You can see an overview of this program on slide 12.

We're conducting a phase 1B clinical trial in patients with advanced non-small cell lung cancer to investigate the safety and tolerability of DV281 as monotherapy and in combination with nivolumab, as well to identify a recommended dose for the expansion part of the study.

Beyond these programs, we're also conducting multiple immuno-oncology pre-clinical research programs, including a cancer vaccine program and a multi-pronged program to develop TLR7 and TLR8 agonists, both as anti-cancer agents and as vaccine adjuvants. We're also evaluating additional candidates to leverage the Heplisav-B 1018 adjuvants in other prophylactic infectious disease vaccines.

With that, I'll turn it over to Michael to discuss our financials.

Michael Ostrach -- Senior Vice President, Chief Financial Officer, and Chief Business Officer

Thanks, Rob. Details regarding our financial results can be found in the press release we issued this afternoon as well as slides 13 and 14 that are posted on our website for today's call. Net product revenue for Heplisav B totaled $3.9 million for the fourth quarter and $6.8 million for the full year 2018. Revenue from product sales is recorded at the net sales price, which includes estimates of product returns, chargebacks, discounts, rebates, and other fees.

Cash, cash equivalence, and marketable securities totaled $145.5 million at December 31, 2018 compared $191.9 million at December 31, 2017. We're planning to borrow $75 million from our non-dilutive term loan agreement during this quarter to support commercial efforts and advance our immuno-oncology platform.

Selling, general, and administrative expenses for the fourth quarter totaled $16.4 million compared to $9.3 million for the fourth quarter of last year. Full year 2018 SG&A expenses were $64.8 million compared to $27.4 million in 2017. These increases are primarily due to full implementation of Heplisav B sales, marketing, and commercial activities, including deployments of our contract sales force, which we're converting to an internal sales force in the next month, implementation of post-marketing studies, and retention of consultants for commercial development services.

The net loss for the fourth quarter was $40 million or $0.64 per share compared to $27.4 million or $0.45 per share for the fourth quarter of last year and the net loss for the 12-month period was $158.9 million or $2.55 per share compared to $95 million or $1.81 per share for last year.

I'll now turn the call back to Eddie for his closing remarks.

Eddie Gray -- Chief Executive Officer and Director

Thank you, Michael. So, we are entering 2019 with good momentum and anticipate solid growth for the company. Our upcoming milestones -- firstly, our Heplisav-B post-marketing study -- the study was initiated in August and is recruiting at the expected rate, with full enrollment targeted for the third quarter. In addition, we are assessing markets beyond the United States and plan to file an MAA in Europe for Heplisav B in the first half of this year.

We are also investigating opportunities to broaden the use of the 1018 adjuvant, which makes Heplisav-B so effective, into additional next generation vaccines. We are collaborating with the Serum Institute of India to develop an improved pertussis vaccine and plan to begin a clinical study of a prototype vaccine later this year.

On the partnership front in immuno-oncology, we are in discussions with a number of pharmaceutical companies to explore the broadening and deepening of our immuno-oncology clinical program. These discussions are a priority activity for the management. The current expansion of our clinical data set will inform important strategic choices, including partnership options, expansion of tumor types, and selection of the best options for progression into registrational studies.

As such, in the course of discussions with prospective partners regarding phase III programs, we may find partners with capabilities and products that will enhance and broaden the TLR9 clinical program and have an interest in supporting the initiatives that we would plan to take forward on our own as well.

So, while I cannot guide to any timing or specific form of arrangement, as each discussion is different depending on the current assets and interests of each potential partner, we are committed to being thoughtful and diligent in determining the best path forward to drive value for our shareholders.

While these partnering discussions are still ongoing, there are plans that we can conduct on our own. For these, we will prioritize tumor types that we believe have a high likelihood of responsiveness to our mode of action in a clear, feasible, and affordable pathway to approval. These include following the assessments of results from the 2-miligram cohorts, we plan to start two studies of SD-101 in combination with anti-PD-1 in the second half of the year, firstly a seamless phase II/III first line in study in patients which have a net cancer.

Compared to first line melanoma, the bar for demonstrating clinical benefits in head and neck is lower and the competitive field less crowded. Secondly, a phase II/III study in patients with melanoma, resistant or refractory to anti-PD-1 therapy.

Finally, a trial that will include multiple HBD-associated malignances, including anal, rectal, and gynecological cancers is also planned for the second half of the year. As with head and neck cancer, although Pembrolizumab is approved or active in these indications, there remains significant need for increased responses that SD-101 has provided in other cancers.

As indicated earlier, while these may form the basis for a Dynavax-only plan, we are incorporating these into our discussions with potential partners as that remains our priority activity. We also plan to report additional SD-101 clinical results and development at major meetings, including the 2-miligram cohort data I mentioned earlier. Finally, at AACR, we will present safety results from our phase I dose escalation study of DV-281 in combination with nivolumab. We plan to initiate a multiple cohort phase two study later this year.

We look forward to what is sure to be a busy and exciting year. Before taking questions, I shall hand over to the operator to take us through that. Thank you.

Questions and Answers:

Operator

Thank you. If you would like to ask a question, please press *1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press *2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the * key.

Our first question is from Anupam Rama with JP Morgan. Please proceed with your question.

Anupam Rama -- JP Morgan -- Analyst

Hey, guys. I'm just following up on one of your comments, Eddie, you mentioned on the data set to inform potential partnership option. Are there any specific pieces of the data specifically thinking about durability and survival that may come at ASCO that are points of interest? And then one on Heplisav -- you mentioned that the customer retention rate is pretty high with doses being from repeat customers, so on those 20% or so that are from first-time customers, are those because the customers haven't had time to reorder or there's no patient demand or have they chosen another vaccination regimen to go with? Thank you very much?

Eddie Gray -- Chief Executive Officer and Director

Thank you, Anupam. The line was breaking up there. So, I'm just going to clarify to make sure we have the right question. The first question, I think, was around durability data later in the year and the second one was about the balance between first customer orders and multiple orders in the Heplisav data. Is that correct?

Anupam Rama -- JP Morgan -- Analyst

That's correct and qualifying those first-time orders, what kind of customers. Thank you.

Eddie Gray -- Chief Executive Officer and Director

Rob, can you comment on the evolution of our durability data and when we're expecting to see available data?

Robert Janssen -- Chief Medical Officer

Yeah. The last durability data we presented as at ESMO. We do anticipate presenting at ASCO. This is in the PD-1-naïve melanoma population which we will be essentially an additional six months to follow up. We have fully enrolled all those patients at this point. So, they are in follow-up. I'm anticipating that we -- I'll trust we'll have meeting and follow-up in the two-milligram group potentially at 10 to 12 months.

Eddie Gray -- Chief Executive Officer and Director

Ryan, could you address the Hepislav, please?

Ryan Spencer -- Vice President of Commercial Operations

Yes. Focusing on the 20% is difficult. Obviously, there are different reasons why customers haven't had a chance to have repeat orders. Some, like you mentioned, will be first time and if they stock in for a month, you can't expect them to have had a repeat order yet. They have different stocking practices, which could be multiple months and in fact, those numbers were based on doses, not actual customers.

We have a situation that can speak to -- not specifically, but we had a rather large customer who took on an initial stocking order that hasn't had a chance to reorder yet either. That actually is a big part of the 20%. So, I think the 80% is a number to focus on as far as having a metric that is meaningful to show that customers to purchase Heplisav and do reorder. The 20% falls into a expected range for a scenario where you're continuing to build new customers every month.

Eddie Gray -- Chief Executive Officer and Director

I think, Anupam, what we're trying to help investors understand is the growth over time in customers who are converting either wholly to Heplisav or converting greater proportions of their business to Heplisav over time and one can see that in a high rate of continued ordering, but also recognizing that by maintaining 20% at this point in time, we're feeding new customers in that.

So, the machine of annuity, if I may call it that way, is being fed with new customers. So, I think we quite like the 80%-20% at this point in time. It's showing that both parts of the development of the business are advancing.

Anupam Rama -- JP Morgan -- Analyst

That's really helpful. Thanks a lot, guys.

Operator

Our next question is from Joseph Cohen with Cowen and Company.

Joseph Cohen -- Cowen and Company -- Analyst

Thank you for taking my questions and congrats on the progress this quarter. I'll start with one on Heplisav. I know the experience is obviously pretty early, but do you have any real world compliance or safety data yet? Have you seen anything surprising or is everything pretty similar to what we saw in clinical study? And then maybe on DV281, have you reached that maximum tolerated dose that you believe you're going to take into expansion cohorts or will you do that by the time of the AACR presentation? Thank you.

Eddie Gray -- Chief Executive Officer and Director

Okay. So, Rob, perhaps you can comment on the compliance or safety data for Heplisav. Then on 281, again, if you can comment. But I'm guessing given our experience in SD-101 and what we've seen in terms of efficacy pattern, we're not necessarily targeting maximum tolerated dose with DV281 anyway.

Robert Janssen -- Chief Medical Officer

Yeah. With respect to compliance, we don't have data at this point with compliance in the post-marketing studies we're doing with Kaiser in Southern California. They will be looking at that when they analyze the data, but that will be in a year or two. The other thing with respect to safety, we do get individual reports of safety events. We're not seeing anything out of the ordinary, nothing that we haven't seen in the past.

With respect to the MTD for DV281, we are right now enrolling in about complete enrollment in our highest dose cohort and we certainly will be looking at whether we reach an MTD. As Eddie mentioned, we think it's probably unlikely that we'll find an MTD.

Joseph Cohen -- Cowen and Company -- Analyst

Great. Thank you.

Operator

Our next question is from Katherine Xu with William Blair & Company. Please proceed with your question.

Roland -- William Blair & Company -- Analyst

Hi, this is Roland on for Katherine. Two questions from me -- first, which is more likely at this point for SD-101, a partner for a phase III study in metastatic melanoma or going on your own in a smaller indication such as head and neck. Second, do you still expect to be operationally ready to enter phase III studies by the end of the first quarter? Thank you.

Eddie Gray -- Chief Executive Officer and Director

So, I think the idea of interest in melanoma-naïve from a partnership point of view and the relative interest on that in comparison to what's going alone on head and neck or anything else really differs from partner to partner. So, it's very difficult for me to be specific. And obviously, I'm not in a position today to talk in detail about individual conversations. So, I think we, as I think I said in my comments, we do take the partnership discussions, confidential as they are, in very high-priority manner.

We do find when we're talking to these customers that each individual discussion is driven by multiple factors and they're different in each case. Each company has its own assessment of market opportunity, how different segments or different tumor types fit into their own portfolio, their own [inaudible], perhaps even what they are trying to achieve or not achieve with their own PD-1. So, I can't really provide a general answer to that one.

In terms of phase III, as Rob's indicated, we are currently collecting all the final 2-milligram data on head and neck and on melanoma refractory. We're putting in place all the preparations ready to go forth with phase III if they're the decisions that we take subject to partnership discussions, but I think it's probably unlikely that we would see any final decisions made on that until we see the full 2-milligram data in those two studies. Is that fair, Rob? Thank you.

Operator

As a reminder, *1 on your telephone keypad if you would like to ask a question. Our next question is from Brian Abrahams with RBC Capital Markets. Please proceed with your question.

Burt -- RBC Capital Markets -- Analyst

Hi, this is Burt on for Brian. Congratulations on the quarter and thanks for taking our question. As you've now reached the inflection point with Heplisav-B sales, are there any additions to or modifications in your approach being implemented to increase uptake on the remaining formularies that you're targeting? I would also be interested in your current thoughts and plans for expanding the label for Heplisav into younger patients, including newborns. Thank you.

Eddie Gray -- Chief Executive Officer and Director

Okay. On the commercial approaches, can you deal with that Ryan, please?

Ryan Spencer -- Vice President of Commercial Operations

I wouldn't say there are massive differences, but we are constantly learning from our interactions with the marketplace and making adjustments to how we approach customers and how we can obviously always improve the efficiencies and the effectiveness of each interaction. But from what I believed the point of your question is a large strategic change -- we're not making major changes to the field structure. There are some minor elements based on our learnings and engagement strategies, but no major changes to our approach to the marketplace.

Eddie Gray -- Chief Executive Officer and Director

On the issue of expanding Heplisav use, I think when one looks vaccination of infants for hepatitis B, there are two important things to remember. Firstly, infants' immune systems remain far more responsive to the traditional alum adjuvants than adults. So, the significant difference and benefit that we can bring to adults in the marketplace isn't as readily available in childhood vaccination. Secondly, hepatitis B in children is very rarely given as a monovalent vaccine. It forms a component path of multi-dose vaccines.

I think we've always felt that it's unlikely even if we were able to deliver a slightly better hepatitis B response that public policy would switch out of these multi-valent vaccines to get the slightly better hepatitis B response in children and create some degree of uncertainty in the rest of the vaccination schedule. So, for those reasons, I think we've always felt it unlikely that we would ever see a pediatric vaccination and I think that's still where our heads are.

Burt -- RBC Capital Markets -- Analyst

Thank you.

Operator

I'm showing no further questions at this time. I would like to turn the call back over to Eddie Gray, Chief Executive Officer, for closing remarks.

Eddie Gray -- Chief Executive Officer and Director

Thank you. I would really just like to thank everybody for joining us today and for your continued interest and support of Dynavax. We very much look forward to updating you on future calls as to our progress through 2019. Thank you very much for your time today.

Operator

Ladies and gentlemen, thank you for your participation in today's conference. This concludes the program and you may now disconnect.

Duration: 31 minutes

Call participants:

Heather Rowe -- Vice President of Investor Relations and Corporate Communications

Eddie Gray -- Chief Executive Officer and Director

Robert Janssen -- Chief Medical Officer

Michael Ostrach -- Senior Vice President, Chief Financial Officer, and Chief Business Officer

Ryan Spencer -- Vice President of Commercial Operations

Anupam Rama -- JP Morgan -- Analyst

Joseph Cohen -- Cowen and Company -- Analyst

Roland -- William Blair & Company -- Analyst

Burt -- RBC Capital Markets -- Analyst

More DVAX analysis

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

10 stocks we like better than Dynavax TechnologiesWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Dynavax Technologies wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of February 1, 2019

Tuesday, February 26, 2019

Top 10 Safest Stocks To Own Right Now

tags:GOOGL,SNCR,MTP,PSX,SFE,NOG,NWN,FWRD,SNAP,FULT,

Last weekend, I was driving through rural Georgia, probably faster than I should have been, listening to the Allman Brothers. It was a hot, sunny August afternoon.

---Recommended Link--- Create A 10%+ Income Stream For Life
We're sitting on a collection of the safest, most generous monthly payers available. And while $11,200 in dividend checks is a welcome addition to anyone's income, investors also love racking up capital gains as high as 446%. Start generating a 10%+ income stream for life today from these consistent companies.

When I entered Taylor County, I started noticing something different about the farmland. For a significant stretch of the mostly deserted four-lane highway, the fields on either side weren't planted with soybeans or cotton or peanuts or corn.

It was photovoltaic solar panels. And I'm not talking about a small cluster used to power some sort of sensor or county extension project.

Top 10 Safest Stocks To Own Right Now: Alphabet Inc.(GOOGL)

Advisors' Opinion:
  • [By Jeremy Bowman]

    The opportunity in autonomous vehicles is likely to rival that of the internet and mobile, which led to dominance of tech companies like Apple and Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL), both of which have been the most valuable company in the world at different moments in recent years, among others. It's easy to see the benefits from driverless tech, which is expected to lead to a lower accident rate, faster commute times, eliminating the hassle of parking and freeing up space, among other benefits. However, the market seems to be ignoring this opportunity. General Motors (NYSE:GM) and Ford (NYSE:F) are still being treated like dinosaurs, while the rise of Alphabet's Waymo seems to have had no impact on its parent's market value. 

  • [By Simon Erickson]

    For example, OZE is creating a cloud-based data analytics platform to help small businesses in Africa, which it's building on Amazon Web Services' infrastructure. And OptiML is creating a machine learning (ML) platform to diagnose eye diseases. It's using NVIDIA's (NASDAQ:NVDA) graphics processing units to recognize pictures of eye conditions, and training its neural network on Alphabet's (NASDAQ:GOOGL) Google Cloud platform.

  • [By Danny Vena]

    Earlier this month when Baidu (NASDAQ:BIDU) reported revenue and earnings that exceeded analysts' consensus estimates -- as well as the company's own forecast -- the company's stock fell nearly 8% on reports that Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG) was planning to reintroduce a censored version of its Google search engine for consumers in China, according to a report in The Intercept.

Top 10 Safest Stocks To Own Right Now: Synchronoss Technologies Inc.(SNCR)

Advisors' Opinion:
  • [By Motley Fool Transcribing]

    Synchronoss Technologies (NASDAQ:SNCR) Q2 2018 Earnings Conference CallAug. 9, 2018 4:30 p.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator

  • [By Max Byerly]

    Synchronoss Technologies, Inc. (NASDAQ:SNCR) Director William J. Cadogan bought 96,152 shares of the business’s stock in a transaction that occurred on Thursday, September 6th. The shares were bought at an average price of $5.87 per share, with a total value of $564,412.24. The purchase was disclosed in a document filed with the SEC, which is available through this link.

  • [By Max Byerly]

    Synchronoss Technologies, Inc. (NASDAQ:SNCR) has received an average recommendation of “Hold” from the nine analysts that are currently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $10.80.

Top 10 Safest Stocks To Own Right Now: Midatech Pharma PLC(MTP)

Advisors' Opinion:
  • [By Money Morning Staff Reports]

    But before we show you our pick, here are the top 10 penny stocks to watch this week…

    Penny Stocks Current Share Price (as of Jan. 5) Jan. 2-5 Gain (as of Jan. 5) My Size Inc. (Nasdaq: MYSZ) $1.66 152.28% Cytori Therapeutics Inc. (Nasdaq: CYTX) $0.47 89.52% DelMar Pharmaceuticals Inc. (Nasdaq: DMPI) $1.675 58.02% CAS Medical Systems Inc. (Nasdaq: CASM) $1.09 55.71% China HGS Real Estate Inc. (Nasdaq: HGSH) $1.83 47.58% Aethlon Medical Inc. (Nasdaq: AEMD) $1.56 43.12% Midatech Pharma Plc. (Nasdaq: MTP) $1.23 43.01% Comstock Holding Cos. Inc. (Nasdaq: CHCI) $1.87 36.5% Cenveo Inc. (Nasdaq: CVO) $1.20 31.82% EV Energy Partners LP (Nasdaq: EVEP) $0.6844 31.62%


    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it's completely free…

  • [By Logan Wallace]

    News articles about Midatech Pharma (NASDAQ:MTP) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Midatech Pharma earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.6134155747452 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

  • [By Shane Hupp]

    Media stories about Midatech Pharma (NASDAQ:MTP) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Midatech Pharma earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.0428548550507 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Top 10 Safest Stocks To Own Right Now: Phillips 66(PSX)

Advisors' Opinion:
  • [By John Bromels]

    When billionaire investor Warren Buffett buys, people take notice. When one of those investments ups its dividend by 14%, they take further notice. Those are two reasons why Phillips 66 (NYSE:PSX) has been getting a lot of attention lately. 

  • [By Garrett Baldwin]

    By following a few simple steps, one IRS directive could help set you up to receive checks of up to $1,795 every single month. Hordes of Americans have already signed their names to the distribution list – and the longer you wait, the greater your risk of missing out on this powerful investment. Click here for more details.

    Three Stocks to Watch Today: FB, AAPL, TSLA Shares of Facebook Inc. (NASDAQ: FB) are under pressure after another government took action on the social media giant's data policies. German regulators announced yesterday that they would limit the company's ability to collect and combine consumer data and target advertising across all of its services. This ruling could make it far more difficult for the firm if it integrates the messaging platforms of Instagram, Messenger, and WhatsApp. Shares of Apple Inc. (NASDAQ: AAPL) are in focus after news broke that it shifted its modem chip engineering team from its supply chain to its internal hardware group. Reuters suggests that it is aiming to develop modem chips in-house after years of buying them from companies like Qualcomm Inc. (NASDAQ: QCOM) and Intel Corp. (NASDAQ: INTC). Such a change could bolster company profits in a big way in the future. Money Morning Chief Investment Strategist Keith Fitz-Gerald argues that Apple stock is a bargain right now. It's just one of several that tap into the unstoppable investment trends that can make you very rich. Learn more right here. On Monday (Feb. 4), Tesla Inc. (NASDAQ: TSLA) announced it was acquiring Maxwell Technologies Inc. (NASDAQ: MXWL), a battery and ultra-capacitor company. This might seem like a typical acquisition where a larger company scales its output by buying a smaller competitor. This is a much different move… On Friday, look for earnings reports from Arconic Inc. (NASDAQ: ARNC), Exelon Corp. (NYSE: EXC), Hasbro Inc. (NYSE: HAS), Phillips 66 (NYSE: PSX), and Ventas Inc. (NYSE: VTR). Millions of Americans Now Entitled to
  • [By Lisa Levin]

    Phillips 66 (NYSE: PSX) reported better-than-expected earnings for its first quarter on Friday.

    The company reported Q1 EPS of $1.04 vs. $0.89 estimates and revenue of 24.05 billion vs. $29.46 billion estimates.

  • [By Ethan Ryder]

    Traders sold shares of Phillips 66 (NYSE:PSX) on strength during trading hours on Friday. $32.81 million flowed into the stock on the tick-up and $85.82 million flowed out of the stock on the tick-down, for a money net flow of $53.01 million out of the stock. Of all companies tracked, Phillips 66 had the 16th highest net out-flow for the day. Phillips 66 traded up $0.58 for the day and closed at $113.60

  • [By Max Byerly]

    Traders sold shares of Phillips 66 (NYSE:PSX) on strength during trading hours on Tuesday. $49.37 million flowed into the stock on the tick-up and $101.62 million flowed out of the stock on the tick-down, for a money net flow of $52.25 million out of the stock. Of all equities tracked, Phillips 66 had the 12th highest net out-flow for the day. Phillips 66 traded up $0.84 for the day and closed at $116.25

Top 10 Safest Stocks To Own Right Now: Safeguard Scientifics, Inc.(SFE)

Advisors' Opinion:
  • [By Shane Hupp]

    THL Credit (NASDAQ: TCRD) and Safeguard Scientifics (NYSE:SFE) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

  • [By Stephan Byrd]

    SafeCoin (SFE) uses the hashing algorithm. Its genesis date was May 25th, 2016.

    SafeCoin Coin Trading

  • [By Ethan Ryder]

    Safestyle UK (LON:SFE) had its price target hoisted by Liberum Capital from GBX 50 ($0.67) to GBX 60 ($0.81) in a research report released on Tuesday. Liberum Capital currently has a hold rating on the stock.

  • [By Stephan Byrd]

    Safeguard Scientifics, Inc (NYSE:SFE) shares were down 1.1% on Monday . The company traded as low as $9.10 and last traded at $9.25. Approximately 5,073 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 100,545 shares. The stock had previously closed at $9.35.

  • [By Joseph Griffin]

    SafeCoin (CURRENCY:SFE) traded 6.5% higher against the U.S. dollar during the 24-hour period ending at 15:00 PM Eastern on June 26th. Over the last seven days, SafeCoin has traded up 19% against the U.S. dollar. SafeCoin has a total market cap of $0.00 and approximately $0.00 worth of SafeCoin was traded on exchanges in the last day. One SafeCoin coin can now be purchased for about $0.0001 or 0.00000001 BTC on cryptocurrency exchanges.

  • [By Shane Hupp]

    Ares Capital (NASDAQ: ARCC) and Safeguard Scientifics (NYSE:SFE) are both finance companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Top 10 Safest Stocks To Own Right Now: Northern Oil and Gas, Inc.(NOG)

Advisors' Opinion:
  • [By Logan Wallace]

    COPYRIGHT VIOLATION NOTICE: “Short Interest in Northern Oil & Gas, Inc. (NOG) Declines By 6.7%” was originally published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/4149947/short-interest-in-northern-oil-gas-inc-nog-declines-by-6-7.html.

  • [By Joseph Griffin]

    Northland Securities assumed coverage on shares of Northern Oil and Gas (NYSEAMERICAN:NOG) in a report published on Wednesday. The firm issued an outperform rating and a $4.00 price target on the energy company’s stock.

  • [By Matthew DiLallo]

    Shares of Northern Oil & Gas, Inc. (NYSEMKT:NOG) are flying high, up 12% as of 10:30 a.m. EDT, after the company reported better-than-expected first-quarter results.

Top 10 Safest Stocks To Own Right Now: Northwest Natural Gas Company(NWN)

Advisors' Opinion:
  • [By Joseph Griffin]

    Shares of Northwest Natural Gas Co (NYSE:NWN) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $70.44 and last traded at $70.20, with a volume of 1123 shares changing hands. The stock had previously closed at $68.82.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Northwest Natural Gas (NWN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Northwest Natural Gas (NWN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Northwest Natural Gas (NWN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    NW Natural (NYSE:NWN) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

Top 10 Safest Stocks To Own Right Now: Forward Air Corporation(FWRD)

Advisors' Opinion:
  • [By Stephan Byrd]

    Forward Air Co. (NASDAQ:FWRD) has been given a consensus rating of “Hold” by the eight analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $64.00.

  • [By Joseph Griffin]

    Forward Air Co. (NASDAQ:FWRD) – Equities researchers at Seaport Global Securities increased their Q3 2018 earnings per share estimates for Forward Air in a research report issued on Tuesday, July 31st. Seaport Global Securities analyst K. Sterling now anticipates that the transportation company will post earnings of $0.80 per share for the quarter, up from their prior estimate of $0.76. Seaport Global Securities also issued estimates for Forward Air’s Q4 2018 earnings at $0.90 EPS, FY2018 earnings at $3.12 EPS, Q1 2019 earnings at $0.69 EPS, Q2 2019 earnings at $0.91 EPS, Q3 2019 earnings at $0.88 EPS, Q4 2019 earnings at $0.98 EPS and FY2019 earnings at $3.46 EPS.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Forward Air (FWRD)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Shares of Forward Air Co. (NASDAQ:FWRD) have been given an average recommendation of “Buy” by the eight analysts that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $64.75.

Top 10 Safest Stocks To Own Right Now: Snap Inc. (SNAP)

Advisors' Opinion:
  • [By Ashraf Eassa]

    To that end, here are three tech stocks that might be tempting for investors but are ultimately bad businesses that investors should avoid: GoPro (NASDAQ:GPRO), Fitbit (NYSE:FIT), and Snapchat (NYSE:SNAP). 

  • [By Chris Lange]

    Snap Inc. (NYSE: SNAP) saw its short interest decrease to 111.17 million, compared to the previous level of 123.20. Shares were trading at $13.02, in a 52-week range of $10.50 to $21.22.

  • [By Leo Sun]

    For that youngest demographic of social media users, Snap's (NYSE:SNAP) Snapchat leads, and it is on pace to remain the top app among teens, with 16.4 million monthly active users (MAUs) this year. It's followed by Instagram -- which Facebook acquired in 2012 -- with 12.8 million MAUs. Facebook's main platform should rank third, with 11.5 million MAUs.

Top 10 Safest Stocks To Own Right Now: Fulton Financial Corporation(FULT)

Advisors' Opinion:
  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Fulton Financial (FULT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Fulton Financial (FULT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Fox Run Management L.L.C. acquired a new stake in Fulton Financial Corp (NASDAQ:FULT) in the third quarter, according to its most recent filing with the SEC. The fund acquired 26,779 shares of the bank’s stock, valued at approximately $446,000.

  • [By Joseph Griffin]

    Hsbc Holdings PLC lessened its stake in Fulton Financial Corp (NASDAQ:FULT) by 88.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 28,236 shares of the bank’s stock after selling 213,318 shares during the quarter. Hsbc Holdings PLC’s holdings in Fulton Financial were worth $502,000 at the end of the most recent quarter.

  • [By Stephan Byrd]

    Fulton Financial (NASDAQ:FULT) last posted its quarterly earnings results on Tuesday, July 17th. The bank reported $0.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.07. Fulton Financial had a net margin of 19.05% and a return on equity of 8.20%. The firm had revenue of $208.12 million during the quarter, compared to analyst estimates of $208.67 million. During the same quarter in the prior year, the business posted $0.26 earnings per share. research analysts expect that Fulton Financial Corp will post 1.15 EPS for the current year.

  • [By Max Byerly]

    Boenning Scattergood reaffirmed their hold rating on shares of Fulton Financial (NASDAQ:FULT) in a research note published on Friday.

    FULT has been the subject of several other reports. Zacks Investment Research upgraded Fulton Financial from a sell rating to a hold rating in a report on Thursday, April 5th. BidaskClub downgraded Fulton Financial from a buy rating to a hold rating in a report on Wednesday, April 4th. Hovde Group reiterated a hold rating and issued a $18.00 price objective on shares of Fulton Financial in a report on Monday, April 23rd. DA Davidson initiated coverage on Fulton Financial in a research note on Monday, March 26th. They set a neutral rating and a $18.00 price target for the company. Finally, Barclays cut their price target on Fulton Financial from $19.00 to $18.00 and set an underweight rating for the company in a research note on Thursday, April 19th. Two analysts have rated the stock with a sell rating and nine have given a hold rating to the stock. Fulton Financial presently has a consensus rating of Hold and a consensus price target of $18.29.

Monday, February 25, 2019

Top 10 Biotech Stocks To Buy Right Now

tags:AMGN,ALNY,ARQL,BIIB,

If you crave risk.

Biotechs often present intriguing, and potentially lucrative, investment opportunities. Share prices can explode on positive trial results or key regulatory approvals. However, buyers beware: these rewards can disappear just as quickly if critical data disappoints. To minimize this risk, we specifically searched for stocks with a high degree of confidence from the Street.

We used TipRanks to ensure that each of these stocks boast a "strong buy" analyst consensus rating right now. In fact, all three of these shares only show 100% buy ratings and huge upside potential of over 100%. With this in mind, let's delve deeper into why the Street is so bullish on these stocks.

Syndax Pharmaceuticals Inc.

Syndax (SNDX) is developing entinostat, a Class I HDAC inhibitor, for the treatment of solid tumors. Shares popped recently following the release of Syndax's first quarter earnings results, but a bigger catalyst on the horizon is the upcoming ASCO oncology conference in June. Syndax is due to present updated data from the ENCORE-601 Phase 2 trial in melanoma and lung cancer.

Top 10 Biotech Stocks To Buy Right Now: Amgen Inc.(AMGN)

Advisors' Opinion:
  • [By Dan Caplinger]

    The iShares biotech ETF has a structure that's familiar to anyone who invests regularly in exchange-traded funds. The ETF tracks an index of nearly 200 biotech and pharmaceutical stocks, with roughly 80% of assets dedicated to true biotechs and the rest split evenly between pharma and life sciences equipment and services providers. Top ETF holdings Biogen (NASDAQ:BIIB), Amgen (NASDAQ:AMGN), and Gilead Sciences (NASDAQ:GILD) make up a total of roughly 25% of the fund's assets.

  • [By Maxx Chatsko]

    Investors are beginning to wonder if bluebird bio is at risk of losing market share before it really even begins life as a commercial company. The latest example: In September Amgen (NASDAQ:AMGN) released promising preliminary data from a small ongoing phase 1 trial, investigating a new immunotherapy as a potential treatment for advanced multiple myeloma. While the initial data release included just five patients, all had failed to respond to between four and six previous treatments. Amgen's drug, AMG-420, a "simpler" immunotherapy compared to the cellular therapies being developed by bluebird bio and Celgene, resulted in a complete remission in four of them. That's very impressive.

  • [By Stephan Byrd]

    Marco Investment Management LLC raised its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 118,601 shares of the medical research company’s stock after buying an additional 5,265 shares during the period. Amgen comprises approximately 3.4% of Marco Investment Management LLC’s portfolio, making the stock its 3rd largest position. Marco Investment Management LLC’s holdings in Amgen were worth $21,893,000 as of its most recent SEC filing.

Top 10 Biotech Stocks To Buy Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:
  • [By Keith Speights]

    I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick -- but with a couple of qualifications. First, I didn't think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

  • [By Brian Orelli]

    Following the Food and Drug Administration (FDA) approval of Onpattro, Alnylam Pharmaceuticals' (NASDAQ:ALNY) first drug to treat hereditary transthyretin-mediated amyloidosis (hATTR), the biotech held a conference call to go over the plan for launch. Here are three things management wants investors to know:

  • [By Cory Renauer]

    After 16 years as a public company, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) finally got the go-ahead to launch its first product earlier this month. Onpattro is the first in a new class of drugs that alter gene expression, but Pfizer, Inc. (NYSE:PFE) just reported some impressive results with a possible competitor that works a lot differently.

Top 10 Biotech Stocks To Buy Right Now: ArQule Inc.(ARQL)

Advisors' Opinion:
  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Money Morning Staff Reports]

    But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we'll show you a small-cap stock with great profit potential in its future…

    Penny Stock Current Share Price Law Month's Gain  Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85% Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40% Vivis Inc. (Nasdaq: VVUS) $0.77 150.41% Adomani Inc. (Nasdaq: ADOM) $1.49 137.68% NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88% Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06% Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12% ArQule Inc. (Nasdaq: ARQL) $4.88 90.74% LiqTech International Inc. (NYSE: LIQT) $0.66 85.60% Transenterix Inc. (NYSE: TRXC) $3.46 77.84%

    While last month's gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.

  • [By Lisa Levin] Gainers Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter. Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants. Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday. SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday. Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results. Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter. Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday. Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday. ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday. Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday. Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Top 10 Biotech Stocks To Buy Right Now: Biogen Idec Inc(BIIB)

Advisors' Opinion:
  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 2.85 million shares from the previous 3.59 million. The stock recently traded at $316.87, within a 52-week range of $249.17 to $388.67.

  • [By George Budwell]

    Not surprisingly, biotech titans Celgene (NASDAQ:CELG) and Biogen (NASDAQ:BIIB) are among the leaders in this ongoing biopharma revolution. So, with that theme in mind, let's attempt to gauge which of these top biotechs is the more attractive long-term buy for investors right now.

  • [By Sean Williams]

    Of course, my "bet against all Alzheimer's drugs" thesis took a bit of a hit last week when biotech blue-chip Biogen (NASDAQ:BIIB), which is working alongside partner Eisai (NASDAQOTH:ESALY), reported positive mid-stage data on blockbuster hopeful BAN2401.

  • [By Ethan Ryder]

    Russell Investments Group Ltd. boosted its holdings in Biogen (NASDAQ:BIIB) by 40.1% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 183,809 shares of the biotechnology company’s stock after buying an additional 52,654 shares during the period. Russell Investments Group Ltd.’s holdings in Biogen were worth $50,222,000 as of its most recent SEC filing.

  • [By Todd Campbell]

    Unfortunately for investors, June's discovery wasn't exciting enough for Sangamo partners Biogen (NASDAQ:BIIB) and Shire (NASDAQ:SHPG). In 2015, Biogen announced a delay to its beta-thalassemia and sickle-cell disease treatment program with Sangamo. And then Shire, a Sangamo collaboration partner since 2012, walked away from Sangamo's hemophilia program.

Saturday, February 23, 2019

3 Reasons Chipotle Mexican Grill Stock Could Rise

On the heels of its strong fourth-quarter financial results, Chipotle's (NYSE:CMG) shares have surged 40% in 2019. Yet even with the stock already up sharply so far this year, plenty of gains may still lie ahead for the popular Mexican-style restaurant chain.

Here's why.

A compass pointing towards the word "growth"

Image source: Getty Images.

New menu items

By appealing to new customer segments -- or giving existing customers more reasons to visit more often -- a restaurant chain can drive increased traffic to its stores and breathe new life into its sales. Chipotle no doubt had this in mind when it recently introduced "Lifestyle Bowls" designed to appeal to people following popular eating plans such as the Paleo and Ketogenic diets. The bowls are intended to make it easier for people to follow these health-focused, but somewhat restrictive, diets, particularly when they're away from home.

"Now more than ever, Americans are embracing new and varied approaches to healthy living and wellness," Chipotle chief marketing officer Chris Brand said in a press release. "We've watched guests custom create lifestyle-specific bowls when ordering in our restaurants, so it made sense to offer delicious options via our online channels that help people easily order bowls with real ingredients that fit their wellness goals." 

Chipotle's new lifestyle bowls should help its brand better resonate with those focused on living healthier lives -- an ever-growing segment of the population that the company's high-calorie meals have largely failed to address up until now. In turn, Chipotle sales could receive a boost from this wellness-focused crowd in the quarters ahead.

Digital sales

Notably, Chipotle's lifestyle bowls are exclusively available through its mobile app and website -- a move designed to fuel the chain's digital initiatives. 

Digital sales are valuable for several reasons. They help to boost customer satisfaction by reducing human error during the order-taking process. Employees that would otherwise be needed to take orders can be redeployed to other food production or customer service roles -- or eliminated altogether in order to reduce labor costs. Online orders also bypass traditional in-store ordering lines, thereby allowing Chipotle to increase sales without increasing customer wait times. All of these benefits help to boost sales, margins, and by extension, profits.

Chipotle knows this, which is why it's doubling down on digital efforts. The company is adding food production lines and order pickup shelves to its restaurants so as to be able to more efficiently service digital orders. It's also testing new mobile order pickup lanes it refers to as "Chipotlanes," which are helping to boost sales at the restaurants which deploy them.

Together, these initiatives are helping to drive Chipotle's digital sales sharply higher, to the tune of 66% growth in the fourth quarter. Better still, investors can expect the company's digital strategy to be a powerful source of revenue growth and margin expansion in the coming years. 

Rewards

Chipotle's new rewards program could be another significant source of growth going forward.

Done right, loyalty programs can have several notable benefits. They can help to drive repeat purchases and increase the frequency of customer visits, particularly during off-peak periods. Perhaps most importantly, rewards programs delivered via digital apps can help restaurants collect valuable customer data, which can be used to design more personalized promotions, thereby boosting the effectiveness of their marketing investments.

In this way, Chipotle's new customer loyalty program should help to fuel further increases in the restaurant chain's sales and profits in the years ahead.

Friday, February 22, 2019

Occidental Petroleum Co. (OXY) Shares Sold by Virginia Retirement Systems ET AL

Virginia Retirement Systems ET AL cut its stake in shares of Occidental Petroleum Co. (NYSE:OXY) by 0.3% in the 4th quarter, Holdings Channel reports. The firm owned 167,000 shares of the oil and gas producer’s stock after selling 500 shares during the period. Virginia Retirement Systems ET AL’s holdings in Occidental Petroleum were worth $10,250,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the business. We Are One Seven LLC bought a new stake in Occidental Petroleum during the 4th quarter valued at $25,000. Country Trust Bank increased its position in Occidental Petroleum by 434.6% during the 4th quarter. Country Trust Bank now owns 417 shares of the oil and gas producer’s stock valued at $26,000 after purchasing an additional 339 shares during the period. Heritage Trust Co increased its position in Occidental Petroleum by 496.2% during the 4th quarter. Heritage Trust Co now owns 465 shares of the oil and gas producer’s stock valued at $29,000 after purchasing an additional 387 shares during the period. Lenox Wealth Advisors LLC purchased a new position in Occidental Petroleum during the 4th quarter valued at $37,000. Finally, JNBA Financial Advisors increased its position in Occidental Petroleum by 891.2% during the 4th quarter. JNBA Financial Advisors now owns 674 shares of the oil and gas producer’s stock valued at $41,000 after purchasing an additional 606 shares during the period. Institutional investors and hedge funds own 79.78% of the company’s stock.

Get Occidental Petroleum alerts:

OXY traded down $0.95 during midday trading on Thursday, hitting $67.30. 49,405 shares of the company traded hands, compared to its average volume of 4,300,320. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.17 and a current ratio of 1.33. The stock has a market capitalization of $51.06 billion, a P/E ratio of 13.44, a P/E/G ratio of 1.45 and a beta of 0.88. Occidental Petroleum Co. has a 52 week low of $56.83 and a 52 week high of $87.67.

Occidental Petroleum (NYSE:OXY) last posted its earnings results on Tuesday, February 12th. The oil and gas producer reported $1.22 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.12 by $0.10. The business had revenue of $4.80 billion for the quarter, compared to analysts’ expectations of $4.39 billion. Occidental Petroleum had a net margin of 21.87% and a return on equity of 18.17%. The business’s revenue for the quarter was up 33.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.41 EPS. Research analysts forecast that Occidental Petroleum Co. will post 3.18 EPS for the current fiscal year.

A number of research firms have recently weighed in on OXY. Atlantic Securities raised shares of Occidental Petroleum from a “neutral” rating to an “overweight” rating and set a $85.00 target price on the stock in a research report on Friday, December 21st. Capital One Financial downgraded shares of Occidental Petroleum from an “overweight” rating to an “equal weight” rating in a research report on Thursday, December 20th. KeyCorp began coverage on shares of Occidental Petroleum in a research report on Thursday, December 20th. They issued an “overweight” rating and a $75.00 target price on the stock. Morgan Stanley cut their price objective on shares of Occidental Petroleum from $96.00 to $88.00 and set a “buy” rating on the stock in a research report on Tuesday, November 20th. Finally, Citigroup cut their price objective on shares of Occidental Petroleum from $97.00 to $95.00 and set a “buy” rating on the stock in a research report on Wednesday, November 14th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Occidental Petroleum presently has a consensus rating of “Buy” and an average price target of $83.32.

ILLEGAL ACTIVITY NOTICE: “Occidental Petroleum Co. (OXY) Shares Sold by Virginia Retirement Systems ET AL” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/4168551/occidental-petroleum-co-oxy-shares-sold-by-virginia-retirement-systems-et-al.html.

About Occidental Petroleum

Occidental Petroleum Corporation, together with its subsidiaries, engages in the acquisition, exploration, and development of oil and gas properties in the United States and internationally. The company operates through three segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops, and produces oil and condensate, natural gas liquids (NGLs), and natural gas.

Featured Story: What is insider trading?

Want to see what other hedge funds are holding OXY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Occidental Petroleum Co. (NYSE:OXY).

Institutional Ownership by Quarter for Occidental Petroleum (NYSE:OXY)

Thursday, February 21, 2019

Contrasting Mirati Therapeutics (MRTX) & Clearside Biomedical (CLSD)

Mirati Therapeutics (NASDAQ:MRTX) and Clearside Biomedical (NASDAQ:CLSD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.

Valuation & Earnings

Get Mirati Therapeutics alerts:

This table compares Mirati Therapeutics and Clearside Biomedical’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mirati Therapeutics N/A N/A -$70.42 million ($2.78) -25.82
Clearside Biomedical $340,000.00 136.57 -$58.97 million ($2.33) -0.62

Clearside Biomedical has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Clearside Biomedical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mirati Therapeutics and Clearside Biomedical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mirati Therapeutics N/A -46.80% -42.71%
Clearside Biomedical N/A -142.46% -102.76%

Risk & Volatility

Mirati Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of -1.3, indicating that its stock price is 230% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Mirati Therapeutics and Clearside Biomedical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirati Therapeutics 0 1 9 0 2.90
Clearside Biomedical 1 2 5 0 2.50

Mirati Therapeutics presently has a consensus price target of $60.00, suggesting a potential downside of 16.41%. Clearside Biomedical has a consensus price target of $12.71, suggesting a potential upside of 776.85%. Given Clearside Biomedical’s higher possible upside, analysts clearly believe Clearside Biomedical is more favorable than Mirati Therapeutics.

Institutional and Insider Ownership

97.9% of Mirati Therapeutics shares are owned by institutional investors. Comparatively, 57.6% of Clearside Biomedical shares are owned by institutional investors. 4.9% of Mirati Therapeutics shares are owned by company insiders. Comparatively, 15.4% of Clearside Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; Array BioPharma, Inc.; and Bristol-Myers Squibb Company to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

Tuesday, February 19, 2019

Top Tech Stocks To Invest In 2019

tags:MB,BV,AMSWA,AMCN,

Adesto Technologies Corp (NASDAQ:IOTS) gapped down before the market opened on Wednesday . The stock had previously closed at $7.45, but opened at $6.80. Adesto Technologies shares last traded at $6.00, with a volume of 4125839 shares traded.

IOTS has been the topic of several research reports. Northland Securities initiated coverage on shares of Adesto Technologies in a research report on Monday, March 19th. They set an “outperform” rating and a $10.50 price objective on the stock. B. Riley initiated coverage on shares of Adesto Technologies in a research report on Tuesday, March 20th. They set a “buy” rating and a $10.00 price objective on the stock. ValuEngine raised shares of Adesto Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Finally, Benchmark raised their price objective on shares of Adesto Technologies from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Friday, June 29th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $10.50.

Top Tech Stocks To Invest In 2019: MINDBODY, Inc.(MB)

Advisors' Opinion:
  • [By Joe Tenebruso]

    Mindbody (NASDAQ:MB) is the leading cloud-based software platform for the global fitness, wellness, and beauty services industry. Mindbody's software helps these often small- and midsize-businesses run their operations more efficiently and profitably, with tools like online appointment setting, staff management, marketing, analytics, and payments, among others. Moreover, with plans starting at $125 per month, Mindbody offers a scalable platform that can grow along with its customers. The company says that its offerings are therefore appropriate for local businesses all the way up to national chains and large enterprises. 

  • [By Beth McKenna]

    Mindbody (NASDAQ:MB) reported first-quarter 2018 financial results after the market close on Tuesday. The online platform provider for the fitness, wellness, and beauty services industries posted revenue growth of 28% and adjusted earnings per share (EPS) of $0.06, versus a loss of $0.03 in the year-ago period.

  • [By Stephan Byrd]

    MINDBODY (NASDAQ:MB) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday.

  • [By Chris Lange]

    MindBody, Inc. (NASDAQ: MB) reported its fourth quarter results after the markets closed on Wednesday. The company said that it had $0.03 in EPS on $49.7 million in revenue. The consensus estimates were looking for $0.01 in EPS and $48.9 million in revenue. Analysts had this to say about MindBody after earnings:

Top Tech Stocks To Invest In 2019: Bazaarvoice, Inc.(BV)

Advisors' Opinion:
  • [By Paul Ausick]

    BrightView Holdings Inc. (NYSE: BV) raised $469 million selling 21.3 million shares at $22, the low end of the expected range. Shares dropped 3% on the first day of trading and closed the week flat.

  • [By Motley Fool Transcribers]

    BrightView Holdings Inc  (NYSE:BV)Q1 2019 Earnings Conference CallFeb. 07, 2019, 10:00 a.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator

  • [By Paul Ausick]

    Below is Renaissance Capital’s list of the second quarter’s 10 largest IPOs ranked by deal size. We’ve also included the stock’s first-day pop (or decline) and its return as of the most recent close. Spotify Technology S.A. (NYSE: SPOT) is not included because its IPO was a direct offering that did not raise any new cash. Spotify shares popped nearly 13% on the April offering date, and the return to date is 27%.

    AXA Equitable Holdings Inc. (NYSE: EQH): $2.75 billion; first-day pop of 1.7%; return to date: 1.3% GreenSky LLC (NASDAQ: GSKY): $874 million: pop of 1.6%; return of −7.9% BJ’s Wholesale Club Holdings Inc. (NYSE: BJ): $638 million; pop and return of 29.4% DocuSign Inc. (NASDAQ: DOCU): $629 million; pop of 37.0%; return of 83.0% Pivotal Software Inc. (NYSE: PVTL): $555 million; pop of 5.0%; return of 71.0% GrafTech International Ltd. (NYSE: EAF): $525 million; decline of 3.7%; return of 23.0% BrightView Holdings Inc. (NYSE: BV): $469 million; decline of 2.7%; return of −2.7% Ceridian HCM Holding Inc. (NYSE: CDAY): $462 million; pop of 42.0%; return of 55.0% Essential Properties Realty Trust Inc. (NYSE: EPRT): $455 million; decline of 2.6%; return of −3.6% PluralSight Inc. (NASDAQ: PS): $311 million; pop of 33.0%; return of 61.0%

    Looking ahead to the third quarter, Renaissance Capital notes 65 companies currently in the IPO pipeline looking to raise $11 billion. Real estate firm Cushman & Wakefield is the both the largest potential IPO ($500 million) and the largest based on trailing 12-month sales ($7.23 billion). The pipeline is again heavy on health care offerings (11), industrials (five), financials (five) and, in a bit of a comeback, energy (four).

Top Tech Stocks To Invest In 2019: American Software, Inc.(AMSWA)

Advisors' Opinion:
  • [By Stephan Byrd]

    American Software (NASDAQ:AMSWA) was downgraded by equities research analysts at TheStreet from a “b-” rating to a “c+” rating in a research note issued to investors on Tuesday.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on American Software (AMSWA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    American Software, Inc. (NASDAQ:AMSWA) announced a quarterly dividend on Friday, August 24th, Wall Street Journal reports. Shareholders of record on Monday, November 19th will be paid a dividend of 0.11 per share by the software maker on Wednesday, December 5th. This represents a $0.44 annualized dividend and a yield of 2.50%. The ex-dividend date is Friday, November 16th.

  • [By Motley Fool Staff]

    American Software (NASDAQ:AMSWA) Q4 2018 Earnings Conference CallJun. 21, 2018 5:00 p.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator

  • [By Stephan Byrd]

    BidaskClub upgraded shares of American Software (NASDAQ:AMSWA) from a hold rating to a buy rating in a research report sent to investors on Monday.

Top Tech Stocks To Invest In 2019: AirMedia Group Inc(AMCN)

Advisors' Opinion:
  • [By Paul Ausick]

    AirMedia Group Inc. (NASDAQ: AMCN) posted a 52-week low of $1.04 after closing down 23% on Wednesday at $1.35. The 52-week high is $3.30. Volume was about 4 million, nearly 20 times the daily average of around 230,000 million shares. The Chinese outdoor advertising company said yesterday that it is terminating a potential go-private transaction.

Monday, February 18, 2019

TrueCar (TRUE) Q4 2018 Earnings Conference Call Transcript

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it

Image source: The Motley Fool.

TrueCar (NASDAQ:TRUE) Q4 2018 Earnings Conference CallFeb. 14, 2019 4:30 p.m. ET

Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

Operator

Greetings. Welcome to the TrueCar Incorporated fourth-quarter and full-year 2018 earnings conference call. [Operator instructions] A question-and-answer session will follow the formal presentation. [Operator instructions] Please note this conference is being recorded.

I would now like to turn the conference over to your host, Alison Sternberg, SVP, investor relations. Ms. Sternberg, you may begin.

Alison Sternberg -- Senior Vice President of Investor Relations

Thank you, operator. Hello, and welcome to TrueCar's fourth-quarter 2018 earnings conference call. Joining me today are Chip Perry, president and chief executive officer; and John Pierantoni, interim chief financial officer. As a reminder, we will be making forward-looking statements on this call, including, but not limited to, statements regarding our guidance and outlook for the first-quarter and full-year 2019, and our outlook in longer term, management's beliefs and expectations as to future strategies, events, and planned product offerings, the effect of the completion of our replatforming initiative, our acquisition of DealerScience, and our ability to develop the best-in-class digital retailing experience, our investment in Accu-Trade, the expansion of the TrueCar Trade dealer network and associated revenue growth, our ability to forecast and grow our OEM revenues and address volatility in those avenues in the aggregate and in revenues from individual OEMs, our ability to improve our user experience and innovate our products and the time frame within which we do so, the effect of our making such improvements in innovations on our financial performance, audience monetization, search ranking and deployment of incremental marketing spending, our efforts to boost our search rankings in organic traffic, our ability to lead the industry by creating an end-to-end car buying experience that benefits all market participants and the outcome of outstanding litigation.

These forward-looking statements are not and should not be relied upon as guarantees of future performance or results. Actual results could differ materially from those contemplated by our forward-looking statements. We caution you to review the Risk Factors section of our annual report on Form 10-K for 2017 filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q for the first, second, and third quarters of 2018 filed with the SEC, and our annual report on Form 10-K for 2018 when filed with the SEC for a discussion of the factors that could cause our results to differ materially. The forward-looking statements on this call are based on information available to us as of today's date, and we disclaim any obligation to update any forward-looking statements, except as required by law.

In addition, we will also discuss GAAP and certain non-GAAP financial measures. Reconciliations of all non-GAAP measures to the most directly comparable GAAP measures are set forth in the Investor Relations section of our website at true.com. The non-GAAP financial measures are not intended to be considered in isolation or as a substitute for results prepared in accordance with GAAP. Now I'll turn the call over to Chip.

Chip Perry -- President and Chief Executive Officer

Thank you, Alison, and good afternoon, everyone. While I'm pleased to say that our business is in a fundamentally much stronger place than it was when we started in 2018, we are disappointed by our fourth-quarter results. Despite achieving solid dealer network and OEM revenue growth, launching trade, and hitting our most important goal for the year, the completion on November 11th of Capsella, our technology rebuild, we encountered some challenges, which led us to miss the midpoint of our revenue guidance by $5 million or 6% and our adjusted EBITDA, which came in at $2.4 million under the midpoint of our guidance range. This means that during the quarter, we grew revenue by 10% instead of our 6% to 8% guidance and our adjusted EBITDA was $8.1 million instead of $10.5 million.

Before highlighting our key accomplishments in the quarter and setting expectations for 2019, I want to review the challenges we faced this quarter that contributed to our shortfall relative to guidance. First, our OEM revenues grew 36% year over year instead of the expected 72% due to the -- due to less-than-expected revenues from our existing OEM clients driven by operational issues during our peak seasonal period. In addition, we had expected a modest contribution from new business during the back half of the quarter that did not materialize. Second, our core franchise and independent dealer revenue grew 5% instead of 9% as planned, primarily due to these factors: stronger-than-expected headwinds in organic traffic on our branded channel, several of our affinity partners did not migrate off our legacy system to our new technology stack until late in the fourth quarter, and we experienced operational challenges on our legacy system before that transition.

And finally, we added fewer independent dealers during the quarter than we had expected. We expect the difficulties with our organic traffic and the volatility in our quarterly OEM revenues will continue to be challenges for us as we begin 2019. As John will outline later, these factors are contributing to our cautious revenue growth guidance for the year. To help organic traffic grow again, we have a holistic multifaceted approach and multiple teams of people working on ways to improve how Google indexes our site.

Post-Capsella, we're thinking SEO first as we design new product experiences. For example, we are working on new Capsella-enabled make-model pages, new car listings pages, and other features that will increase user engagement. And we believe these improvements will boost our search rankings over time. In our OEM business, which grew 29% in 2018, we expect some clients will continue to participate on our platform intermittently as they pilot expanded programs and as we navigate their internal budgeting processes.

As our OEM business continues to scale, our ability to pinpoint quarterly revenue contributions were less precise than we like it to be. However, we remain confident in our ability to deliver solid OEM revenue growth on an annual basis, and we continue to have productive dialogue with a robust pipeline of potential OEM clients. Another reason for our cautious guidance in 2019 is that the benefits we expect to achieve from upcoming Capsella-enabled improvements to our user experience will not be realized until they are fully implemented, and so they are not sufficiently visible at this time. As a reminder, the completion of Capsella was a necessary foundational step that now allows us to evolve our product suite much more rapidly toward the performance of our long-term vision.

You've heard me say that product innovation of TrueCar has been limited for the past three years by the limitations of our legacy platform. And over the last year, we dedicated most of our engineering resources to completing Capsella. Now, we can focus our efforts on product innovation and in improving a fundamental consumer experience. I would also emphasize that our goal with Capsella was to replace our legacy data center-based platform with a modern cloud-based platform.

And that while doing this, we were only able to replicate our legacy products experience because it was not feasible to rebuild the tech stack while simultaneously innovating a new experience. This means that while our technology platform now allows us to make much more rapid product improvements, we are starting off this year with an experience that is largely the same as it was before Capsella launched. Importantly, we've also observed some meaningful improvements to certain segments of our user experience simply as a result of the transition itself. As an example, we've seen some encouraging improvements in our used car engagement, highlighted by increased site speed and higher used vehicle conversion rates.

In fact, we've launched more new product features than our used car experience in the past quarter than we were able to launch in the previous two years combined. This performance was achieved with only one small dedicated cross-functional team. Post Capsella, we've now deployed a vast majority of our product and engineering teams to innovate across our product suite. I would now like to preview our broader product road map for the year and some of the exciting product improvements we plan to introduce.

First, in 2019, we plan to make improvements in our consumer experience, designed to give users more control of their interactions with dealers and unlock new ways of monetizing a higher percentage of our audience. We're calling this our new consumer-centric interaction model. In the second half of 2018, we tested some key elements of this model that yielded significant growth in attributed sales. Our focus this year is to test and refine this model and develop our go-to-market approach in order to monetize these incremental unit volume.

Second, we believe there is an opportunity to refresh and expand upon our core pricing value proposition. We are already working to improve the way our pricing is presented and explained, and to ensure that we help consumers, while clearly identify vehicles that are competitively priced. Third, in 2018, we improved our used car experience and plan to make further strides in 2019 to improve it while delivering more values for our ideal customers. We anticipate these improvements will move our used car offering closer to competitive parity and leverage our unique capabilities, including member discounts for used cars, market-based pricing context and value attribution for dealers.

Fourth, today we're announcing our minority investment in Accu-Trade, our partner for the TrueCar Trade product. Through this investment, we are securing our role as the exclusive third-party provider of Accu-Trade's product suite and we are participating in the growth of its leading-edge wholesale marketplace tools for dealers. Based on the success of our TrueCar Trade pilot with Accu-Trade last year, we expect that trade dealer count and revenues will continue to accelerate as we focus on growing consumer awareness of this new product, which is also a key puzzle piece of our future end-to-end consumer experience. Also during Q4, we acquired DealerScience, which we believe will allow us to develop the best-in-class digital retailing experience for both consumers and dealers.

As you can see, this product roadmap represents the opening of a new chapter at TrueCar. Now that we are on the other side of our replatforming initiative, we are focused on innovating our products as we continue automation to be the most transparent branded automotive and to serve as a catalyst that dramatically improves the way people discover, buy, and sell cars. Over the course of my tenure here, we have worked to build the foundation for this moment, and we are excited about the growth that our new platform will enable. While this past quarter was a disappointing end to a challenging year, it is also a reminder of the complexity of what we are trying to build and the reward that we believe will come when we build it.

Even though Capsella is now complete, USAA's unit performance is back to where it was in mid-2017, and we have 1,200 more dealers than we did the year before. We are forecasting only 5% to 7% revenue growth instead of the acceleration I signaled last year for three principal reasons: first, we do not yet have adequate visibility to the many benefits that we believe will be activated by the ramp of Capsella-enabled product improvements that are now in the works. Some of these improvements will launch in Q1 and Q2, and our new consumer-centric interaction model will be tested in Q2 with a national rollout expected in Q4. We believe that these product enhancements will enable meaningful positive step functions in our financial performance.

And until we understand it better, we are not building them into our guidance. Second, one of our major OEM clients is taking a pause from our marketplace in Q1. Third, we continue to experience headwinds in our organic traffic. Due to these factors, we now believe our return to healthy double-digit revenue growth will begin a year later than I signaled last year.

That said, I am no less confident about the potential for our business and the positive impact we can have in our category. Please remember, we are in a large, highly competitive, and fragmented industry that has been entrenched in a single way of doing business for decades. Here at TrueCar, we are not focused on bringing only incremental improvements to the existing way business is done. Rather, our ambitions are larger.

We are trying to fulfill the industry's largest unmet need, which is the creation of a seamless, transparent end-to-end car buying experience, benefiting all market participants. Key players in our industry talk about the need to move car buying into the 21st century. I still believe we are the only player in the space that has all the components necessary to get this done. And while the path has proven rocky at times, we remain undeterred and confident in our ability to lead the industry to this solution.

That is why I joined TrueCar in the first place, and why we continue to be excited to stay on course to achieve our objectives. I will now turn it over to John to walk you through our results for the fourth-quarter and full-year 2018, and our guidance for 2019.

John Pierantoni -- Interim Chief Financial Officer

Thank you, Chip, and good afternoon, everyone. As Chip highlighted earlier, we were disappointed with our fourth-quarter financial results where we grew top-line revenue 10% as compared to our guidance of 16%. Now I'll walk you through the details of our fourth-quarter performance and our expectations for 2019. Revenue in Q4 of '18 totaled $91.1 million, up 10% over Q4 of '17 and below our revenue guidance of $95.5 million to $97.5 million.

For all of 2018, revenue was $353.6 million, up 9% over the prior year. Revenue from our franchise dealers totaled $67.4 million in Q4 of '18, up 5% over Q4 of last year. Franchise dealer count grew 4% year over year to 12,674 and average monthly revenue from franchise dealers was $1,780 in the quarter, which was up 2% year over year. For more context, we had expected 9% growth in revenue from our franchise dealers with the lower growth rate of driven by lower unit volumes, which I'll further describe in a few moments.

In all of 2018, revenue from franchise dealers totaled $266.1 million, up 7% over 2017 as we were up 532 franchise dealers over last year and average monthly revenue per franchise dealer was $1,787, which is roughly flat year over year. Moving to our Indi business. Revenue from our independents was $8.8 million in the quarter, up 4% over Q4 of last year as compared to 10% expected growth. The lower growth in the fourth quarter was driven by fewer independent dealer additions than expected.

Our independent dealer count was up 23% year over year to 3,655 while average monthly revenue per independent dealer decreased 13% year over year to $826. The lower average revenue per dealer is due to the continued shift in our strategy toward more small-to-midsize independents. For all of 2018, revenue from independent dealers was $35.5 million, up 11% over 2017 while 2018 average monthly revenue per independent dealer was down 7% year over year to $892. Moving to trade.

During the fourth quarter of '18, we generated $1.2 million of trade revenue from approximately 640 rooftops. We launched our national trade advertising campaign in the fourth quarter and are now active in 65 markets. Although our fourth-quarter results for trade did not match our expectations, we are very pleased that we built a large national network during the pilot phase of this program to serve as a launch pad to grow in '19. We believe that our recent investment in Accu-Trade will enable us to further accelerate growth and innovation of our Trade offering.

And now for our OEM business. During the fourth quarter of 2018, incentive revenue totaled $8.2 million, up 36% over Q4 of '17. The increased year-over-year revenue was due to strong performance of an incentive program with one of our newer OEM customers. As Chip highlighted earlier, we had expected over 70% year-over-year growth in our OEM business in the fourth quarter.

This miss was due to less-than-expected revenues from our existing OEM clients, driven by operational issues during the peak seasonal period. In addition, we had expected a modest contribution from new business during the back half of the quarter that did not materialize. Through all of 2018, our OEM incentive revenue was $30 million, up 29% from $23.3 million in 2017. And finally, forecast, consulting, and other revenue was $5.1 million in Q4 of '18, which was up 15% year over year.

This increase was due to our [Inaudible] business, where they completed a number of consulting projects as they closed out the year. For the full year of '18, our forecast, consulting, and other revenue was down 2% year over year to $19 million. And now for some insights into unit volumes. Units in the quarter totaled 257,017, up 7% year over year, but below our guide of 262,000 to 267,000.

The unit miss was driven by our branded channel, where ongoing headwinds in organic traffic were greater than expected. Additionally, we experienced some operational issues associated with our legacy platform during the migration to Capsella, which created modest unit softness for a few of our affinity partners during the quarter. For all of 2018, units totaled 1,005,029, up 5% year over year. In our branded channel, we generated 97,174 units in Q4 of '18, which was down 6% year over year and we generated 393,987 units for all of 2018, which was down 2% year over year.

Despite the miss in our guidance, we understand the key levers for growing our branded channel going forward, a strong post Capsella focus on our site experience and architecture that will benefit our organic search ranking and enable a productive deployment of incremental marketing dollars. And during extended partner channel, we generated 90,583 units in Q4 of '18, which was up 18% year over year. This growth reflects strong performance in our membership and finance segments. And for all of 2018, our extended partner units totaled 339,212, also up 18% year over year.

And finally, our USAA channel generated 69,260 units in Q4 of '18, up 17% from last year. Similar to last quarter, our USAA business rebounded from user experience improvements, which offset 2017 site changes that caused temporary dip in performance of this channel. And for the full year, USAA members purchased 271,830 vehicles via the car-buying service, which is up 4% over 2017. The new-used unit mix was stable year over year with 68.8% new and 31.2% used in 2018 as compared to 68.6% new and 31.4% used in 2017.

Monetization in Q4 of '18 was $334 per unit, up from $328 per unit in Q4 of last year. And monetization for the year was $333 per unit versus monetization of $319 per unit in 2017. The increases in quarterly and annual year-over-year monetization were primarily due to increased incentive revenues from our OEM business. Turning to expenses and margins, where all of the following metrics are on a non-GAAP basis, unless otherwise stated.

Gross profit in Q4 of '18 was $83.4 million, up 10% from Q4 of '17 while gross margin was 91.5% in Q4 of '18 versus 91.2% in Q4 of last year. And for all of 2018, gross profit was $324.1 million, up 9% from the prior year and gross margin was 91.7%, roughly flat from 2017. We demonstrated operational efficiencies in our technology and product spend where expenses totaled $12 million or 13.2% of revenue in Q4 of '18 as compared to $13.4 million or 16.1% of revenue last year. Through all of 2018, technology and product expenses were $50.8 million or 14.4% of revenue as compared to $51 million or 15.8% of revenue in 2017.

Sales and marketing expenses were $52.5 million or 57.7% of revenue in Q4 of '18 as compared to $44.8 million or 53.9% of revenue in Q4 last year. Within sales and marketing, we spent $16.1 million on TV, radio, and digital to drive TrueCar channel customer acquisition. This compares to $15.1 million in spend this time last year. And cost per sale for Q4 increased by 14% from $145 per unit last year to $160 per unit this year, primarily driven by the $1.6 million investment in our trade marketing as we launched our national advertising campaign.

Excluding the trade marketing spend, cost per sale for Q4 increased by 3% year over year to $150 per unit. Partner revenue share and other expenses totaled $17.8 million in Q4 of '18 as compared to $12.9 million in Q4 of last year. The increase in expenses was driven by the mixed shift in units toward USAA and other extended partner channels and increased revenue share from our growing OEM business. And our affinity partner cost per sale increased 17% year over year to $112 in Q4 of '18.

Finally, our sales, headcount, and other costs were $18.6 million in Q4 of '18, up 11% from $16.8 million this time last year. The increase in cost reflects the expansion of our dealer sales and service teams to support our larger dealer network and our plans for new product offerings. Through all of 2018, sales and marketing expenses totaled $199.5 million or 56.4% of revenue as compared to $175 million or 54.2% of revenue in 2017. Moving to G&A.

We continue to demonstrate operational efficiencies, where Q4 2018 expenses totaled $10.7 million or 11.8% of revenue as compared to $10.2 million or 12.3% of revenue in Q4 of '17. And for the full year of 2018, G&A spend totaled $41 million or 11.6% of revenue as compared to $41.1 million or 12.7% of revenue in 2017. Our adjusted EBITDA totaled $8.1 million or 9% of revenue in Q4 of '18 as compared to $7.5 million or 9% of revenue in Q4 of '17. The items excluded from adjusted EBITDA for Q4 of '18 included depreciation and amortization of $5.9 million and stock-based compensation of $8.9 million.

Our GAAP net loss for the quarter was $6.4 million or a net loss of $0.06 per share as compared to a GAAP net loss of $8.5 million or a net loss of $0.08 per share in Q4 of last year. Our net loss in all of 2018 totaled $28.3 million or a net loss of $0.28 per share as compared to a net loss of $32.8 million in 2017 or a net loss of $0.35 per share. Our non-GAAP net income for the quarter was $2.7 million or $0.03 per share as compared to a non-GAAP net income of $4.9 million or $0.05 per share in Q4 of '17. And for the year, our non-GAAP net income was $11.1 million or $0.11 per share as compared to $7.2 million or $0.08 per share in 2017.

We continue to maintain a strong balance sheet with cash balances totaling $196 million at the end of the year. I'd like to highlight that our cash balance reflects a reduction of $27 million related to our acquisition of DealerScience in December but doesn't yet reflect the $22.9 million investment we just made in Accu-Trade. And now turning to guidance. I'll share our outlook for 2019 and the first quarter of the year.

As Chip highlighted earlier, we are opening a new chapter here at TrueCar. Having completed Capsella, we are now capable of rapidly innovating our product experience. We believe that our product roadmap will enable us to make meaningful improvements to our consumer experience and ultimately drive more consumers to purchase vehicles at one of our TrueCar certified dealerships. In spite of the opportunity ahead of us, we are setting our annual guidance at a modest 5% to 7% top-line revenue growth.

This plan does not include the potential benefits from post-Capsella product improvements as we don't yet have a line of sight into the specific revenue growth we can realize from these improvements. As we test and launch product changes throughout 2019, we'll be in a better position to estimate the related revenue opportunities. In addition, we are entering this year with headwinds in our branded channel and have some volatility in our OEM business with one of our newer OEM customers pausing their program in Q1 of '19. While we have plans in place to work through these challenges, we believe it is prudent to put forth a more cautious plan in 2019.

For the year, we expect to generate revenue of $371 million to $378 million. Here is the breakdown of the key components of revenue: we expect 2019 dealer revenue to be $320 million to $325 million, representing year-over-year growth of 5% to 7%. Given some of the headwinds in the branded channel, we expect roughly flat unit volumes in 2019 as compared to '18. We believe growth in dealer revenue will be driven by the expansion and rollout of our trade offering, revenue from our new DealerScience business and modest growth in our core business.

We expect our dealer count to grow by about 1,000 dealers in 2019 with the majority in the independent category, similar to 2018. In 2019, we expect OEM incentive revenue to be between $32 million and $34 million, representing 7% to 13% growth over 2018. As I described earlier, one of our larger new OEM partners is pausing their program in the first quarter of '19. And because of this pause and potential volatility as we grow in scale our OEM business, we are putting forth a more cautious guidance plan in '19.

However, we're still very encouraged by growth opportunities in this business and our pipeline opportunities remain quite strong. As far as annual adjusted EBITDA, in 2019, we expect to modestly grow our adjusted EBITDA margins. We are guiding to adjusted EBITDA of $35 million to $40 million, which represents an adjusted EBITDA margin range of 9.5% to 10.5%. To help generate this margin, in January, we reduced our staff by 65 people or approximately 9% of our workforce, reducing our compensation expense by about $10 million in 2019.

We are also reducing other operating spend by $6 million year over year, yielding a total savings of approximately $16 million. In addition, for the year, we estimate noncash stock-based compensation expense to be in the range of $37 million to $39 million, compared to stock-based compensation expense of $37.2 million in 2018. For 2019, we estimate depreciation and amortization expense will be approximately $23 million to $25 million, compared to $22.7 million in 2018. For the first quarter of 2019, we expect revenue to be in the range of $84 million to $86 million or year-over-year growth of 4% to 6%.

And we expect adjusted EBITDA to be in the range of $3 million to $5 million producing adjusted EBITDA margins of 3.5% to 5.5%. The drop in our adjusted EBITDA margins in the first quarter is due to lower anticipated OEM revenues as previously mentioned. We expect our adjusted EBITDA margins to improve in subsequent quarters. And now, I'll turn it over to questions. 

Questions and Answers:

Operator

[Operator instructions] Our first question comes from the line of Steve Dyer from Craig-Hallum. Please proceed with your question.

Steve Dyer -- Craig-Hallum Capital Group -- Analyst

Thanks. Good afternoon. You've talked a bit about a challenge in organic traffic, and I was wondering if you could be a little bit more specific as to what your perception is that's causing that, if it's an algorithm-based change or what's driving that year over year?

Chip Perry -- President and Chief Executive Officer

Yes. Thank you, Steve. The challenge to our organic traffic flowed from changes that were made in the search algorithm last year and we felt the effects of them more strongly than expected in the second half of the quarter. What's happening is that our search rank have fallen from where they used to be as a result of changes in the algorithm.

Today, when consumers come to TrueCar through search engine, they encounter our price support page. And right on the price support, we have ask the consumers to quickly register without any warm up. So, that experience is suboptimal. We've known it for quite a while compared to when folks come to our home page, they get a chance to understand our value proposition, go through multiple steps [Inaudible] their car before they are asked register, much more of a warm-up, and they have good engagement there.

However, with the Google search traffic and Bing search traffic, we don't have an optimized experience. We've known that we need to improve the landing page essentially, the make-model landing page for consumers to see when they come at TrueCar through a search engine. Pre-Capsella, we weren't able to build those pages with all of our resources to focus on rebuilding our infrastructure. Now that we are on the other side of Capsella, we've got a bunch of things we are working on that over time, we believe, we will have a nice positive effect on our search ranks.

They include much better make-model information pages that are rich in content, user/owner reviews, model information, side-by-side comparison tool, also new car list pages that will have a number of new car listings that consumers can consume, which will keep them on our pages longer, create more engagement as well as other tools that will produce stronger engagements, including our new consumer-centric interaction model. All those things, we think, will lead to higher search ranks and we believe that organic weakness will be witnessed for a while but something that we'll be able to power through over time, can't predict exactly when. But we've got a lot of work in progress to make that happen and we understand the gaps in our experience that are needed to be filled in order to produce much stronger search ranks.

Steve Dyer -- Craig-Hallum Capital Group -- Analyst

All right. That's helpful. And then, sort of related, what was -- and I may have missed this, what was your net funnel efficiency in the quarter?

John Pierantoni -- Interim Chief Financial Officer

So, NFE for the fourth quarter, just give me one second. It was about 1.32%.

Chip Perry -- President and Chief Executive Officer

So, Steve, well, [Inaudible] it's basically up sequentially and up over the course of the year but we think that NFE by itself is not a really great holistic metric as much as it used to be in judging the performance of our marketplace, our platform. And that's because we have traffic coming at us through so many pathways now, including search, that affect the ultimate NFE. We're looking at conversion and close rate economics across all of the audience channels and pathways into our marketplace. We are managing them closely, but NFE is a number that we think this business [Inaudible] as it used to be, even though it's improved, but I'm not trying to standing on high ground here, saying it's a tremendously positive indicator given the other things that are happening in the business right now.

Steve Dyer -- Craig-Hallum Capital Group -- Analyst

OK. Gotcha. And then, I guess, lastly from me and I'll hop back in queue. The independent revenue per dealer seems to get sort of at an outsized rate.

Is there any reason that would be different for the independents versus the bigger franchises or sort of what's driving that? Thanks.

Chip Perry -- President and Chief Executive Officer

You bet, Steve. And on your point about organic -- when we see less organic traffic, our NFE actually improves because organic has less conversion and close rates potentially when some of our other audience channels do. So that's part of the reason why you're seeing NFE rise. So with respect to independents, it's we have a different strategy there than we do a franchise dealer.

Overall, in the second half of the year, we added about 800 dealers like we said we would. And within the independent category, we did quite well in terms of total dealer count. What's going on here is that, we are bringing more smaller dealers into our marketplace. There is a long tail of independents out there and they offer a rich array of inventory in local markets.

And we wanted to make sure that our consumers, particularly those among our affinity partners, who often have a strong need for used cars and a diverse selection, we want to broaden the array of vehicles including those offered by smaller independent dealers. So, the smaller dealers have smaller inventories that receive to a lead and therefore their average monthly subscription fees in our independents is smaller than our franchise area. So, it's basically a mix question around the size of the independent dealers. Overall, the revenue is flat, given that but -- and we believe we can produce some growth there going forward.

But in the last quarter at least, we did see a modest degradation in rate per dealer.

Steve Dyer -- Craig-Hallum Capital Group -- Analyst

Thank you.

Operator

Our next question comes from the line of Mark Mahaney from RBC Capital Markets. Please proceed with your question.

Shweta Khajuria -- RBC Capital Markets -- Analyst

Great. This is Shweta for Mark. Could you talk about the OEM partner that paused in Q1? Anymore details around why and how long do you think that may be? Is it a Q1 issue? Is it a one-time issue? And then, could you also talk about just generally, how you see the traffic growth post the SEO challenge through the year? Thank you.

Chip Perry -- President and Chief Executive Officer

OK. Our OEM business, as I've said is composed of some anchored clients like SPA and Mercedes. And over the past year, we've added others to our client roster, including Nissan, and Ford have come along as well as [Inaudible] and a couple of others. We have one of those newer clients that paused in the first quarter.

They've given us very positive feedback over the course of the year that the program is working quite well. But the budget for that particular program got light and so, they had to take a pause. And really what this is, is an indication of is a more bigger opportunity or another way of looking at a problem we have which is that the budget we are accessing today is the budget pool -- the spending pool tend not to be on the side of the OEM's business that drives digital marketing through what's called an upfront purchasing process. We don't participate in the upfront today.

And we need to get ourselves more embedded on that side of the OEM purchasing system, and we are. Our clients tend to have opportunistic budgets for their intensive program, but they also market incentives much more broadly digitally, and so we haven't yet cracked into the upfront. Our team is working hard to do that over the course of this year and next year. So, over time, we believe that we'll be able to get stronger more consistent broader participation by OEMs, more of them and deeper and more consistently.

But today, we are still subject to the intermittent use, even though if you interview our clients, they would tell you they are very pleased with the programs they were running with us. And even prospective clients when they look at the benefits we are proposing they say, it sounds good. We now need to find a budget. So we are working on accessing the larger digital marketing spending tools that our clients have and there is plenty of it out there we just not accessing it today.

John Pierantoni -- Interim Chief Financial Officer

And in regard to your question regarding traffic as well, so for purposes of 2018 for the fourth quarter, traffic was down obviously in part driven by the organic problems that -- challenges that we've been having. We see that trend continuing, so we were down 10% in the fourth quarter. We see it being a little bit higher as we enter into 2019 without maybe phasing off toward the back-end of the year. That being said, we are anticipating units overall to be flat for the year.

So, we're seeing some incremental conversion going through in particular, some of the changes that we started to already see with Capsella on our used side where we turn it over to Capsella earlier. So, overall, units flat and traffic down in regards to some of the things we are seeing with search organic. 1

Chip Perry -- President and Chief Executive Officer

And obviously what's happening here is that coming out of a weak fourth quarter, we had anticipated increasing our marketing budget this year. So, it's giving us a slow start on our revenue line, but holding our fire marketing. So, that's part of it. We're also holding our fire until we see some improvements in our user experience and the higher engagement that it's results in.

And so -- and we haven't built into this model the forecast, as John mentioned, assumptions around improvements and conversion rate or close rate as a result of the end unit growth as a result of the upcoming improvements in our user experience unless they are going to be many. We're going to be improving how our pricing service presents it. On the new car side, we got a bunch of improvement in play and then we've got the testing of our consumer-centric interaction model which enable consumers that much more control over when their name goes to a dealership and that will help make them much more comfortable about registering, which will enable us to have a much higher level of unit sales that are matched into our dealership, but we're not making any assumptions about the effect of those positive improvements in this forecast. That's another reason why we're being cautious in our unit growth plans that underlies our financial forecast.

Shweta Khajuria -- RBC Capital Markets -- Analyst

Thank you.

Operator

Our next question comes from the line of Heath Terry from Goldman Sachs. Please proceed with your question.

Daniel Powell -- Goldman Sachs -- Analyst

Hi, thanks. This is Daniel Powell actually on for Heath. Just a couple quick questions from us. On the advertising side of things, I know you guys saw a little bit more deleverage on your ad spend year over year than you had in the last couple of quarters.

I realize there's some challenges on the SEO side with traffic, but anything interesting from a paid customer acquisition side, maybe outside of some of these trade-in products that you paid to -- during the quarter that you are seeing from a customer acquisition standpoint? And then, on the monetization side, excluding the incentives, which looks like it was down a bit year over year primarily due to the softness on the independent dealer side. But is there any updates that you can give us on sort of the mix of dealers paying on a subscription basis either, as a percent of revenue or percent of dealers? Thanks.

John Pierantoni -- Interim Chief Financial Officer

Sure, I can get started on the customer acquisition question. So, in regards to TC GC cost per sale, we were modestly up about 3% on a year-over-year basis. The cost per sale excluding the trade investment of the $1.6 million I referred to was about $150. And so that's kind of in line with what we've seen so at a reasonable level, but I think we are comfortable with that level.

We haven't invested incrementally into additional marketing and we are holding off right now. And so we have better experience with the product. So as we make changes later on and the right time we will invest more heavily on the acquisition side. In regards to your second question, with respect to what part of the business is on subscription versus pay-per-sale, so couple of things to highlight.

So, one, in regards to the State of California used to be on a sales guarantee basis and that transition offers sales guarantee on to a flat rate subscription effective January of this year. So subsequent to that transition, you will see that our pay-per-sale business is between 35% and 40% on a unit basis. A little bit higher, about 45% on a dealer basis. [Inaudible] those are all your questions, Daniel?

Daniel Powell -- Goldman Sachs -- Analyst

Yes, that's great. Thanks guys. I'll hop back in the queue.

John Pierantoni -- Interim Chief Financial Officer

Great.

Operator

Our next question comes from the line of Sameet Sinha from B. Riley & Company. Please proceed with your question.

Sameet Sinha -- B. Riley and Company -- Analyst

Yes, couple questions. So, John, if you can remind us, I think when you are giving guidance for 2019, you spoke about franchise dealer count and I think you said it's going to be flat. So, can you talk about why that is the case? Has there been any change in the relationship there? Secondly, if you could shed some more light on the operational issues that you are seeing on the OEM side and what exactly happened. And it seems like it's not going to be fixed this year or at least can you give us a timeline for when that gets fixed.

And my third question is, in terms of the SEO issues, Chip, you kind of laid out all the other things that need do to fix your Google algorithm rankings. So, when can we expect you to start layering that -- those changes? And how quickly can you get them out and how quickly will it take for Google to kind of index and recognize those changes? Thank you.

John Pierantoni -- Interim Chief Financial Officer

Sure. I'll start off with your dealer count question, Sameet. So for purposes of our franchise and our Indi dealers, we are anticipating some growth this year, it will be little bit less than last year. We are anticipating roughly 1,000 dealers, that being skewed a little bit more toward the independents.

So, 800 or so independent with the delta coming from your franchise dealers. So, we are seeing some modest growth in that area as we're working through some of these challenges with respect to traffic and units staying roughly constant. We are a little bit more modest in our expectations around the franchise dealer business but it's something that we're obviously working through. Chip, [Inaudible] the dealer question.?

Chip Perry -- President and Chief Executive Officer

Yes, sure. There are two kinds of operational issues I mentioned in my part of the talk was that, one was about OEM and we did say, we did have problems delivering incentive quotes to consumers in the back half of the last quarter. Also internal operational issues and we address them and they are not affecting our system today. The other kind of issue we had was with our -- with some of our affinity partners.

We were not able -- we weren't able for a few weeks in the second half of the quarter to get leads properly delivered to dealers, and that affected some of our units in the quarter. So -- and that one is like more of an issue that happened post-Capsella, but it was quickly addressed and we don't have that catching us anymore now either. So, I think that the operational issues that we saw in the fourth quarter are not in play currently and we don't expect them to rear their heads again [Inaudible] issues right now anytime in the future. And regarding the SEO improvements that I mentioned, that you just ask about, Sameet, you are going to start to see some changes to our website in the next quarter or two.

You are going to see more listings show up that can be called by Google. Today our site, our new product listings are not visible to Google at all. We're going to make them visible through listing search and we are going to start to be building out these make model information pages. But that will happen during the second half of the year.

So, I think this is a issue we are going to be dealing with through 2019, but I do believe that the real positive user experience changes and Google-centric pages that we're building in the site will help us turn this problem around. It's hard to forecast right now exactly when but we will start to see changes in the site and we'll point them out on the next call. We'll be able to see what we've done in every quarter that's going to accumulate over the course of the year.

Sameet Sinha -- B. Riley and Company -- Analyst

Thank you.

Operator

And our next question comes from the line of Kyle Evans from Stephens. Please proceed with your question.

Kyle Evans -- Stephens -- Analyst

All right. Thanks for taking my question. Chip, do you -- I think you mentioned 2Q test for the consumer-centric dealership interactions and a 4Q launch. I'm just trying to understand the priorities of everything that you are trying to get done this year and I am a little surprised if that's happening so late in the year.

Could you give me your thoughts on where that stands versus trade and SEO and some of the operational issues you face today?

Chip Perry -- President and Chief Executive Officer

Sure. So, trade is an important initiative growing rapidly out in the field. It's not very product-intensive here in Santa Monica. So that doesn't task our team very much.

With respect to our new consumer experience, that is the top priority of the company actually. And I think the plan we have rolling out is similar to what I just said last year, where I said we will be testing it in the first half and rolling it out in the second half. So, we will be taking a portion of our audience and we'll also be selecting some geographic markets, where we're going to launch this new experience. And we are going to do it -- two or three different versions in order to evaluate, which variants on this experience performs the best and then once we understand the lift that we are getting in that sales because we are going to see a much higher rate of registration.

We are going to see a much higher level of mass sales and we did see that in the modest test we did it last year. And so, we are going to as we wouldn't see those results in the test, which we're going to conduct in the second quarter. It'll take us a quarter or so to turn in what the best go-to-market strategy is with our dealers to help them understand the value of this new experience for them and work through what the best pricing model will be that will enable the dealers to benefit as well as TrueCar from this new experience. So, we expect to help the dealers become more efficient overall, get more net sales from TrueCar, and at the same time, on the basis of higher net sales, we'll be able to make a strong case for them sharing a higher share of their marketing wallet with us.

So that needs to be tested and optimized during the course of the year and rolled out in the second half. That's why it takes some time and I do single that last year, it wouldn't be one big bang and that's really a theme of post-Capsella. Capsella being completed, enables us to innovate our experience in a way we haven't been to in the three years I've been here. That's why I went to [Inaudible] emphasized this is a new chapter in our history.

We can now actually make changes in this shopping experience. We aspire to help consumers really understand pricing very well on the cars they want to buy, introduce them to an upfront transactional price that's better they can find elsewhere typically on the market and they have lot of improvements in just the core functionality of the site planned for the first and second quarter. Those weren't profitable before we bought Capsella. The new user experience testing wasn't possible.

So all those things give us tremendous strong positive excitement for the future here. But because we don't have the metrics yet of the impact of those changes on our business, we are not building them into our plans yet. But, I believe, like I said earlier that this will enable us to have a strong acceleration beginning in 2020. I would love to have been able to say it's happening in this year, but we're not able to do that given the softness that we see in our organic traffic and the stores that we are getting an OEM.

But there is an acceleration coming. And if the -- it'll be principal product-led, along with our sales teams engaging with dealers to realize the higher level of revenue growth based upon higher level of net sales of dealership. That's our goal. We want to help dealers see the fruits of stronger volume through TrueCar and we have a clear roadmap to getting that this year.

Kyle Evans -- Stephens -- Analyst

You mentioned that the trade was a little behind in 4Q. Can you update us on maybe what's happening there? And then talk about your outlook for 2019 for that product? Thanks.

Chip Perry -- President and Chief Executive Officer

Yes, trade achieved its goal of having a national network at the end of the year. We didn't have as quite a higher network as we expected to by the end of the fourth quarter, but we had over 600 dealers and we're ahead of that now. And from the first quarter we can see we are on pace to accelerate, the additions -- the competitive additions we had in the fourth quarter of last year. And we believe that we will be able to add roughly a 1,000 dealers for that network over the course of this year as we continue the strong promotion, the awareness- and the awareness of that product growth among the dealer body, and now with our investment in Accu-Trade, I think we're going to see a bit stronger mindshare with the dealers because they realize that this program is backed by the best used vehicle valuation system in America, one that proves a very strong value in a highly transparent way and has an array of appraisal features that the dealers use when they bring cars in that can really help the used car side of their business.

So, we're very excited about this product not only for it has its own individual generator, but also because it's a very strong -- as part our roadmap to creating [Inaudible] experience very much toward the end of the experience based upon the consumer being able to get a transparent view of all of the economic elements of the transaction, meaning the monthly payment, which will be driven by trade, the price of the car, their down payment and the lending long-term. Trade is very key to enabling us to -- to enable consumers to get that full transparency they desire and our acquisition of DealerScience will complement our Trade product very nicely because the DealerScience we have best-in-breed monthly payment calculation tool that dealers can place on their website as well as we will be able to integrate over the course of dealer. And TrueCar that will enable consumers to get penny perfect deals of what their monthly payment will be on the vehicle they want to buy before they go to the store, which generally isn't possible today in America. [Inaudible] drives with Trade and DealerScience toward our vision of helping care buyers get a much more transparent view of the entire car deal, not just the price of the car.

Kyle Evans -- Stephens -- Analyst

But just to be clear, that $1.2 million in the quarter, was that below your expectation?

Chip Perry -- President and Chief Executive Officer

Yes, relative to where we started at the beginning of the year, yes. We wanted to get to $2.5 million. We are seeing us do $1.2 million. We still believe that that will have 2 to 4 x growth off of that base in 2019.

Kyle Evans -- Stephens -- Analyst

OK. Thank you.

Operator

Our next question comes from the line of Dan Kurnos from The Benchmark Company. Please proceed with your question.

Dan Kurnos -- Benchmark Company

Great. Thanks. Just following up on that kind of line of questioning. I don't know, John, I apologize if I missed this.

Did you give kind of full year new dealer product expectation? And did you give the same level of granularity for Q1 that you gave for the full year outside of traffic?

John Pierantoni -- Interim Chief Financial Officer

I can certainly provide you guys a little bit more details in regard to some of the new revenue streams that we're seeing. In regards to specifically talking about trade, it gives you about $1.2 million in trade revenue in the fourth quarter. We're seeing something that's more in the line of, say, $8 million to $10 million number in 2019 on an annual basis. In regards to some of the newer products, so DealerScience gives us a small revenue stream.

We purchased that company in regards to their technology base, but we think there's an opportunity to grow that business. It did come with a nice base of initial dealers and we do plan to integrate that into TrueCar to help and continue to grow that business. And that's probably going to be in the tune of about half the size of your trade business is what we are anticipating right now. There is also a couple of other products that were currently in test with that we'll anticipate launching in the back half of the year, which will be a modest amount of revenue that we think in the back half of the year.

So, those are some of the newer revenue streams. In regards to the first quarter, in regards to how that phases out, I'd say, we'll see some modest growth in trade in the first quarter. You will also see some of DealerScience come in as well. So you see a couple of those components with the new product that I mentioned more toward the back-end of the year.

Dan Kurnos -- Benchmark Company

And just on the -- going down a little bit further, just in terms of the units and net franchise, I'm just trying to make sure we have this right in terms of getting to your guide. Is OEM going to be up in Q1 even with the pause because of the new other guys that you've added to the platform? And are units kind of flattish throughout the year? Or does that have maybe some more impact upfront and then eases although comps are kind of somewhat varied across the year?

John Pierantoni -- Interim Chief Financial Officer

No problem. So, in regards to the OEM business, year over year for Q1, we're anticipating OEM is going to be flat. So that's what we're expecting and that's driven by the pause of a large OEM program that we had talked about in the prepared remarks. In regards to units throughout the year looking at total units, we do see units being flat on a total basis throughout the year, modestly up in the first quarter and then really roughly flat for the rest of the year but very, very low-single digits.

And that's impart driven by some of the challenges that we've seen in regards to the organic traffic that we described.

Dan Kurnos -- Benchmark Company

Got it. That's super helpful. Thanks. And then, just going forward, I don't know if this is a question you guys can answer now with sort of the tech issues that are plaguing you but now that you are past Capsella, and understanding that you still want to get more aggressive on marketing, how should we think about tech and dev leverage over time or is it more just a reallocation of resources and to going after marketing once you get past some of the issues?

Chip Perry -- President and Chief Executive Officer

So, I would say, we had issues, some issues, modest issues in transitioning off of our ol legacy system. It's not significant. We're delighted with the launch of Capsella. We have TrueCar and our all affinity partners on that new cloud-based platform.

We are not plagued at the moment with tech issues. We had them last quarter but not now plagued. We believe that there is a lot of work to do here. We held our tech and dev expense kind of flat as a percentage of revenue last year and we expect to, John, help me, I think it's going to be relatively flat this year again.

John Pierantoni -- Interim Chief Financial Officer

We expect to have a comparable level of stand and t he resources that were focused on the pre-Capsella environment and transitioning over are now being deployed into product improvement and new opportunities. But we are seeing that that's -- we expect the spend to be roughly comparable and flat margins.

Chip Perry -- President and Chief Executive Officer

So, we spent three rebuilding our infrastructure. Now we completely redeployed that entire team to focus on innovation for the first time in three years. So, we're very excited about the path forward, which will [Inaudible] of fairly rapid product improvement chart listing experience. I mentioned much better presentation of the pricing curve, pre-prospects and post-prospects, improvements to our user experience.

And then the beginning of testing of our new consumer-centric interaction model which is a major sort of change in the experience and the value we deliver to dealers. So, all that's going to be executed this year and we've got a very strong roadmap, dedicated team, milestone, and we will be reporting on our progress on those each quarter. We'll be able to see how we are getting to segment. We are in a much better place than we were a year ago, much better place.

The tech stack is completely rebuilt. 100% of our effort now basically is on innovation. It wasn't that way before. We have more OEMs in our portfolio overall and we believe that over the course of the year, we'll get back some of the ones who were implemented last year and the one that paused.

Our trade product is accelerating in its growth and we have the best-in-breed digital retailing tool now in our portfolio as well. So, the company is in a much stronger place than it was a year ago. Obviously, we had some short-term headwinds we are working through this year. But I am very pleased with the strategic progress we've made along the milestones that we have set for ourselves in creating a platform that now can let us catapult forward with a much better car-buying experience for consumers.

And because we have a value proposition of dealers where our fees to dealers on a per car basis are much less than their marketing average they pay as a result of all the other channels, as we grow volumes into their business, we believe we'll have a strong foundation from which grow the share of their wallet and grow our revenue line. So, this company is poised to grow very nicely. Once these product improvement starts to take hold as this year proceeds.

Dan Kurnos -- Benchmark Company

Last one for me, if I could. Just on USAA, it always comes up from investors and the like and usually on these calls, so I figure just this to ask in light of some of the challenges you are facing. You did have a good quarter, but when is that negotiation up again? And does any of that headwinds you are facing concern you over getting that done at favorable terms?

Chip Perry -- President and Chief Executive Officer

We expect to grow our USAA channel this year by modest single-digit year over year consistent with the historical performance. So, USAA will benefit from the user experience change we make over the course of the year. So we're not building those into this forecast. So, we grew modestly last year.

We expect to some modest growth again this year. And with respect to our upcoming renewal, we will be -- our current agreement expires in February 2020, USAA has been and remains a very important partner to TrueCar. We will continue to collaborate well with them and we're looking forward to improving the performance of that channel this year based on the product evolution as it proceeds. At this point though, we're not going to be commenting about our current or forthcoming contract negotiations with them and so we are going to be quiet on that until we actually have a deal.

Dan Kurnos -- Benchmark Company

Fair enough. Thank you, guys.

Operator

Our next question comes from the line of Nick Jones from Citi. Please proceed with your question.

Nick Jones -- Citi -- Analyst

Hi, thanks for taking the question. I just had two quick ones. One on the trade product, do you have any kind of -- any number you can give us GPU uplift for the dealers using the product. I understand the consumer side, but what kind of value are the dealers, who are using it getting out of it? And then, the second question is, on search -- organic search.

How do you feel TrueCar stacks up in launch of keywords against the competition and is that somewhere they can be shot up quickly?

Chip Perry -- President and Chief Executive Officer

OK. So, you mentioned GPU uplift, industry term for gross profit per unit. The dealers when they bring cars in on trade, either they -- they either wholesale them or retail them and in either case, for their acquisition price determines the wholesale or retail profit on the other end. And for the consumer, the higher price they get, the happier they are with the deal.

So, what our TrueCar trade product does is produce a win-win for both sides of this transaction. Consumer comes away understanding better why their car is worth what is worth because the tool gives them a dynamic real-time update of the value based upon all of their input parameters, and they really like that. And also that dynamic real-time update capability, the dealers find useful to help them establish the correct value for the car after it's presented them with the dealership. The way this product works is, the consumer provides all the information about the car before they come to the store and they get an offer that is guaranteed, assuming the car is represented correctly.

If the car is represented correctly, the participating dealer will pay the full price of the car. And if there is any issue that is discovered at the dealership during the inspection that weren't revealed by the consumer in their earlier usage of the tool, then there will be some deduction. There also could be some increases in value of the vehicle. If the consumer, for instance, didn't know there is a optional moon roof on the car, and there is, they will get the credit for that through the tool.

So the tool gives the dealer and the consumer complete transparency instantaneously on why the car has the value it has and the value is pegged at a good solid wholesale market number. And so, it works with the consumer, works with the dealer and the dealers who are working with tell us that the transparency and the specific way in which it helps them identify the effects on the vehicle's value of specific issues that both the consumer and the dealer are viewing together during the collaborative walk around, it helps the dealer establish a more correct value for the car on a more objective rational basis. And for that reason, it takes a process that is murky and makes it more transparent and specific. And many dealers are telling us that they are able to have a better acquisition prices as a result.

At the same time the consumer walks away understanding specifically why the car is worth what it's worth. So there truly is a win-win and the dealers are giving us good feedback in their perspective and consumers are telling us that their satisfaction is much higher and they rate the overall transaction that they have with the dealer much more positively when they're using TrueCar Trade compared to when they are not using our tool. And with respect to your question on SEO, so the main battleground among our kind of company -- third-party companies in the search world is make-model search terms. Make-model search terms sometimes modified by geography, sometimes modified by price, by features that usually make model.

So the make-model searching reward companies that have a long legacy and tradition of serving the research upper funnel car shopper. TrueCar wasn't built that way. TrueCar was built as a lower funnel closer to the transaction pricing engine that resulted in consumer-dealer introduction. So the company wasn't built that way and we built our traffic and our brand through largely direct advertising both online and offline.

And so, SEO is never built into this company from the beginning in contrast to other companies in our space, who were built the exact opposite way, Google-centric right at the get go. We're playing catch up here obviously. Our plan is to serve upper-funnel consume